#### Check for updates

#### OPEN ACCESS

EDITED BY Rolf Teschke, Hospital Hanau, Germany

#### REVIEWED BY

Yunling Xu, Zhejiang Academy of Traditional Chinese Medicine, China Guoyi Tang, The University of Hong Kong, China

#### \*CORRESPONDENCE

Ya Zhang, i zhangya19780711@163.com Guo Chen, i chenguoxx@cdutcm.edu.cn Zhao Jin, i dr.jinzhao@cdutcm.edu.cn

RECEIVED 13 December 2023 ACCEPTED 10 April 2024 PUBLISHED 09 May 2024

#### CITATION

Zheng S, Xu Y, Zhang Y, Long C, Chen G, Jin Z, Jiang S, Chen J and Qin Y (2024), Efficacy and safety of traditional Chinese medicine decoction as an adjuvant treatment for diabetic nephropathy: a systematic review and metaanalysis of randomized controlled trials. *Front. Pharmacol.* 15:1327030. doi: 10.3389/fphar.2024.1327030

#### COPYRIGHT

© 2024 Zheng, Xu, Zhang, Long, Chen, Jin, Jiang, Chen and Qin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Efficacy and safety of traditional Chinese medicine decoction as an adjuvant treatment for diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials

Shuyu Zheng<sup>1</sup>, Yunxi Xu<sup>1</sup>, Ya Zhang<sup>2</sup>\*, Caiyi Long<sup>1</sup>, Guo Chen<sup>3</sup>\*, Zhao Jin<sup>4</sup>\*, Shui Jiang<sup>5</sup>, Junyu Chen<sup>1</sup> and Yulian Qin<sup>1</sup>

<sup>1</sup>Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China, <sup>2</sup>Department of Endocrinology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China, <sup>3</sup>Department of Infectious Diseases, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China, <sup>4</sup>Chengdu University of Traditional Chinese Medicine, Chengdu, China, <sup>5</sup>Good Clinical Practice Department, Chengdu Jingdongfang Hospital, Chengdu, China

**Objective:** This study aimed to assess the efficacy and safety of traditional Chinese medicine decoction as an adjunctive treatment for diabetic nephropathy in systematic evaluations.

**Methods:** A comprehensive search was conducted in PubMed, Web of Science, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang databases, covering the period from January 2013 to July 2023. The search was restricted to randomized controlled trials (RCTs) conducted within the past decade that investigated the use of TCM decoction as an adjunctive treatment for diabetic nephropathy. The control group received western medicine treatment, while the intervention group received TCM decoction in addition to the conventional treatment. Endnote and Excel were employed for literature management and data organization, and Revman 5.3 and Stata 16 software were used for the analyses.

Results: 66 RCTs involving 6,951 participants were included in this study. The clinical efficacy of TCM decoction as an adjunctive treatment for diabetic nephropathy was found to be significantly higher than that of the control group (OR = 3.12, 95% CI [2.70, 3.60],  $l^2 = 0\%$ , p < 0.00001). The incidence of adverse events did not differ significantly between the intervention group and the control group (OR = 0.94, 95% CI [0.60, 1.48],  $l^2 = 0\%$ , p = 0.94). According to the secondary outcomes of renal function and blood glucose indicators, the intervention group showed better therapeutic efficacy compared to the control group. The most frequently used TCM categories were tonifying medicine, blood-activating medicine, astringent medicine, diuretic medicine, heat-clearing medicine, and laxative medicine. Among them, the top five frequently used Chinese medicine were Astragalus mongholicus Bunge [Fabaceae; Astragali mongholici radix](58 times), Salvia miltiorrhiza Bunge [Lamiaceae; Radix et rhizoma salviae miltiorrhizae] (42 times), Dioscorea oppositifolia L. [Dioscoreaceae; Dioscoreae rhizoma] (38 times), Poria cocos (Schw.) Wolf [Polyporaceae; Poria] (38 times), and Cornus officinalis Siebold & Zucc. [Cornaceae; Corni fructus] (35 times).

**Conclusion:** The combined use of TCM decoction with western medicine in the treatment of diabetic nephropathy can enhance clinical effectiveness and 2 This is a provisional file, not the final typeset article achieve superior therapeutic effects in comparison to western medicine alone, without significant risks.

**Systematic Review Registration:** https://www.crd.york.ac.uk/PROSPERO/ #recordDetails, identifier [CRD42022529144].

KEYWORDS

adjuvant therapy, traditional Chinese medicine, Chinese medicine decoction, diabetic nephropathy, meta-analysis

## **1** Introduction

Diabetes Mellitus (DM) is a metabolic disorder caused by a combination of genetic, autoimmune, and environmental factors. In China, the total number of individuals with diabetes is approximately 120 million (International Diabetes Federation, 2023). It is estimated that 20%–40% of diabetes patients in China also suffer from diabetic nephropathy, which is the leading cause of end-stage renal disease (ESRD) and a major cause of mortality among diabetes patients (Barrera-Chimal et al., 2022; Naaman and Bakris, 2023).

Traditional Chinese medicine (TCM) decoction is commonly used as an adjunctive therapy for treating diabetic nephropathy in China. It has been shown to improve patient symptoms and slow down the progression of diabetic nephropathy, with good clinical efficacy and safety. Liu et al. (Liu et al., 2022) found that both Huang Kui Capsules and Zi Cui Yin Decoction were able to reduce Scr levels and improve symptom scores in patients. Furthermore, Zi Cui Yin Decoction was found to have a positive impact on correcting gut microbiota dysbiosis. Another study by Sun et al. (Sun et al., 2022) revealed that Danggui Buxue decoction improved insulin resistance, chronic inflammation, and lipid accumulation in diabetic nephropathy mice. Additionally, Wang et al. (Wang et al., 2018) discovered that Shenqi Dihuang decoction significantly intervened in the inflammatory response, reduced proteinuria, protected renal function, improved endothelial function and hemorheology, restored microcirculation to normal levels, or demonstrated good therapeutic efficacy in early-stage diabetic nephropathy patients.

Currently, most studies have been limited to small-sample clinical trials conducted at a single center or non-clinical trials. There is a wide variety of TCM decoctions used, considerable differences in outcome measures, or a low level of evidence. Therefore, there is a need for a systematic analysis and evaluation of the effectiveness and safety of TCM decoction as an adjunctive treatment for diabetic nephropathy.

# 2 Materials and methods

## 2.1 Protocol and registration

The meta-analysis was registered with the International Prospective Register of Systematic Reviews (PROSPERO) under the registration number CRD42022529144. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), its protocols, and the PRISMA-extension statementfor meta-analysis to report the current results (Hutton et al., 2015).

## 2.2 Search methods

A systematic search of the PubMed, Web of Science, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang databases for randomized controlled trials (RCTs) was conducted from 2013 to the present that investigated the use of traditional Chinese medicine decoction as an adjunctive treatment for diabetic nephropathy (DN). The Chinese search terms included "diabetic nephropathy& Xiao ke nephropathy" and "traditional Chinese medicine& Chinese botanical medicine& Chinese medicine decoction" and "randomized controlled trailsand clinical trials". The English search terms included "diabetic kidney diseaseand diabetic nephropathyand diabetic" and "Chinese Medicine & Chinese Botanical Medicine & Traditional Chinese Medicine & Chinese Medicine decoction" and "Randomized Controlled Trial & Clinical Trial & Intervention Study & Clinical Study". There were no language or geographic restrictions. In addition, we manually supplemented the included studies by examining the references of the identified articles that met the inclusion criteria. The search strategies are provided in Supplementary Table S1.

## 2.3 Data extraction

After screening and assessing the identified literature by reviewing titles, abstracts, and full texts, eligible RCTs were included based on the following inclusion and exclusion criteria. Inclusion criteria:

- (a) Participants: There were no gender or race restrictions. Adult individuals (aged 18 years and above) diagnosed with DN based on clinical assessment were included.
- (b) Intervention and comparison: The control group received Western medicine treatment, while the intervention group received traditional Chinese medicine decoction in addition to the control group's treatment.
- (c) The study should report at least one of the following outcomes: primary outcome - clinical effective rate, adverse event rate. Secondary outcomes - renal function indicators: serum creatinine (Scr), urinary albumin excretion rate (UAER), blood urea nitrogen (BUN), 24-h urinary total protein (24 h-utp) and blood glucose indicators: fasting plasma glucose (FPG), glycated hemoglobin (HbA1c).

Exclusion criteria:

- (a) Non-randomized controlled trials, retrospective studies, animal experiments, and review articles;
- (b) Participants: Exclusion of individuals with renal dysfunction caused by other reasons.
- (c) Intervention: Intervention group using other traditional Chinese medicine treatments, such as Chinese patent medicine, Chinese medicine pills, Chinese medicine injections, acupuncture, massage, or ear acupuncture.
- (d) Outcomes: Data not accurate or outcome measurement incomplete, and unable to obtain data from the original authors.
- (e) Duplicate publications.

#### 2.4 Study selection

Two researchers (Shuyu Zheng and Yunxi Xu) independently conducted data collection using the aforementioned search methods and inclusion criteria. The following information was extracted:

- (a) Publication information (title, first author, publication year).
- (b) Study characteristics (study design, treatment duration).
- (c) Participant characteristics (number of participants included, age, gender, duration of diabetes mellitus (DM), stage of diabetic nephropathy (DN)).
- (d) Intervention (intervention drugs, dosage, frequency, route of administration for the control group; composition of traditional Chinese medicine decoctions, dosage, frequency of administration for the intervention group, based on the control group).
- (e) Outcomes (primary and secondary outcomes). For continuous data, mean and standard deviation were extracted. For categorical data, the number of events and total count were extracted.

In cases of disagreement between the two researchers, a third researcher (Caiyi Long) made the final judgment.

#### 2.5 Critical appraisal

Using the bias risk assessment tool provided by Cochrane, two researchers (Junyu Chen and Yulian Qin) independently assessed the quality of the included RCT studies and cross-checked their assessments. The assessment consisted of seven components: random sequence generation, allocation concealment, blinding of participants and personnel, completeness of outcome data, reporting bias, and other biases. Three categories were used to assess the methodological quality of the studies: "high risk of bias," "low risk of bias," and "unclear bias." In cases of disagreement between the two researchers, a third researcher (Shui Jiang) made the final judgment.

## 2.6 Statistical analysis

EndNote 9.0 was used for literature management, Excel was used for data organization, and RevMan 5.3 and Stata 16.0 were employed for statistical analysis. For binary outcome variables, the effect measure statistic used was odds ratio (OR), while for continuous outcome variables, the effect measure statistic used was mean difference (MD) or standardized mean difference (SMD). A 95% confidence interval (CI) and  $I^2$  test were used to assess heterogeneity. If  $p \ge 0.05$  and  $I^2 < 50\%$ , a fixed-effect model was used for analysis. If p < 0.05 and  $I^2 \ge 50\%$ , a random-effects model was used for analysis. A significance level of  $\alpha = 0.05$  was used for meta-analysis. Sensitivity analysis was conducted using the one-by-one elimination method. Publication bias was assessed using funnel plots and Egger's test.


# **3** Results

## 3.1 Research and selection

After database searching, a total of 6,706 relevant studies were obtained. After removing 2,476 duplicate records, 4,230 studies were screened based on their titles and abstracts, resulting in the exclusion of 3,648 studies. Among the remaining 582 studies, full-text reading was conducted, and finally, 66 studies were included (Yi and Mianzhi, 2013; Angui, 2014; Liping et al., 2014; Yalian, 2014; Bailong et al., 2015; Beide and Tingting, 2015; Jialing and Yan, 2015; Jianmin, 2015; Jingjing et al., 2015; Ming et al., 2015; Ting et al., 2015; Lige, 2016; Shulan et al., 2016; Tao et al., 2016; Xiaojing et al., 2016; Ni et al., 2017; Ping and Lin, 2017; Rucui et al., 2017; Xiaoli et al., 2017; Aimin et al., 2018; Huajun et al., 2018; Liwen et al., 2018; Min et al., 2018; Shijian and Chunying, 2018; Xiaoyi, 2018; Xingguo et al., 2018; Changsong et al., 2019; Chenhui et al., 2019; Fangqiang et al., 2019; Gangyi et al., 2019; Jili and Hengji, 2019; Ling, 2019; Rong and Xiabo, 2019; Suqin et al., 2019; Xiaoze et al., 2019; Yangxi et al., 2019; Yangxia et al., 2019; Zhixiong et al., 2019; Dandan, 2020; Wei et al., 2020; Xinxin et al., 2020; Yalan et al., 2020; Bing and Guobin, 2021; Sun et al., 2022; An et al., 2022; Chuanfu et al., 2021; Chuanyong et al., 2022; Cuiqing et al., 2021; Duanyang et al., 2023; Haitao et al., 2022; Hongye et al., 2021; Huaizhi et al., 2021; Jiali and Dong, 2023; Jiang and Fang, 2021; Jinfeng et al., 2021; Lei et al., 2022; Li et al., 2022; Meizhen et al., 2022; Ping et al., 2022; Ruixuan et al., 2023; Xiaomei et al., 2021; Xin et al., 2023; Xue et al., 2023; Yali et al., 2020; Yan et al., 2022; Ying et al., 2021; Yu et al., 2022). Details of the selection process are presented in Figure 1.

#### 3.2 Study characteristics

These 66 included studies involved a total of 6,915 patients, with 3,487 in the intervention group and 3,470 in the control group. The sample size of both the intervention and control groups was greater than 30, and all patients were from China. The average age of the intervention group ranged from 42.76 to 70.03, while the average age of the control group ranged from 45.37 to 69.21. The treatment duration ranged from 4 to 52 weeks. The included patients had DN stages ranging from III to IV. Interventions in the control group included conventional treatment, ACEI/ARB drugs, hypoglycemic medications, ipratropium bromide, prostaglandins, glutathione, and alfacalcidol capsules. The intervention group received traditional Chinese medicine decoctions in addition to the interventions were




classified into various groups based on their compositions. The criteria for classifying groups of Chinese medicines is the Clinical Chinese Medicine (Zhang et al., 2004), which delineate 12 groups including the Guizhi Fuling formula (GF) group, Yiqi Zishen formula (YZ) group, Shenqi Dihuang formula (SD) group, Yiqi Huayu formula (YH) group, Jianshen Huayu formula (JH) group, Buyuan Tongluo formula (BT) group, Wenshen Jianpi Huayu Tongluo formula (WJHT) group, Yiqi Yangyin Tongluo formula (YYT) group, Gushen Jianpi (GJ) group, Jiangtang Baoshen formula (JB) group, Bushen Yiqi Tongluo Huazhuo (BYTH) group and Huoxue Yishen formula (HY) group. A total of 105 different Chinese medicine from 14 categories were used, with the top five most frequently used Chinese medicine being Astragalus mongholicus Bunge [Fabaceae; Astragali mongholici radix], Salvia miltiorrhiza Bunge [Lamiaceae; Radix et rhizoma salviae miltiorrhizae], Dioscorea oppositifolia L. [Dioscoreaceae; Dioscoreae rhizoma], Poria cocos (Schw.) Wolf [Polyporaceae; Poria], and Cornus officinalis Siebold & Zucc. [Cornaceae; Corni fructus]. The studies' characteristics, criteria for assessing clinical effectiveness rates, interventions, outcomes and the names of Chinese medicine decoction prescription are provided in Supplementary Tables S3-S8. All the Chinese medicine listed in the prescriptions have been categorized based on the standards set

forth by *Clinical Herbal Medicine*. All Chinese medicines appearing in the prescription have been taxonomically validated in Kew Science resources and the *Pharmacopoeia of the People's Republic of China*, 2020 edition (National Pharmacopoeia Committee, 2020; Trustees of the Royal Botanic Gardens and Kew, 2023). All the formula names were written in Chinese Pinyin and a table of standard terminologies for Chinese Pinyin is provided in Supplementary Table S7. For the scientific methodology of the writing, we consulted the guidelines by Rivera, D., et al. Please refer to Supplementary Table S8 for details (Rivera et al., 2014). We have adhered to the guidelines for reporting the composition, including preparation and included two PDFs of the assessment using the ConPhYMO tool. Please refer to the Appendix on page 89–90 for further information (Heinrich and Jalil, 2023).

#### 3.3 Bias risk assessment results


The quality of the included literature was evaluated using the Cochrane risk assessment tool. Among the 66 included studies, 50 studies used random number table allocation, and one study used dice rolling for random allocation (Jinfeng S, 2021), which were assessed as low risk. Two studies allocated participants based on the



	Experim	ental	Contro	ol.		Odds Ratio	Odds Ratio			Experime		Control			Odds Ratio		ds Ratio
	Experim				Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl		Study or Subgroup 2.1.1 GC	Events	Total Ex	vents T	otal W	feight N	A-H, Fixed, 95% CI	MILE	xed, 95% CI
.1.1 New Subgroup	Lyents	rotal	Lycins	- vtdl	**Citra	In the Fixed, 53% CI	m-n, rixeu, 25% G		2014 Angui J	27	30	16	30	1.4%	7.00 [1.96, 31.60]		
014 Angui J	27	30	16	30	0.7%	7.88 [1.96, 31.68]			Subtotal (95% CI) Total events	27	30	16	30	1.4%	7.88 [1.96, 31.68]		
014 Yalian H	27	31	22	37	1.2%	4.60 [1.33, 15.88]		_	Heterogeneity: Not app	icable		10					
015 Jialing Y	39	43	27	43		5.78 [1.74, 19.19]			Test for overall effect Z	= 2.91 (P	= 0.004)						
015 Jianmin Y	44	48	37	47	1.4%	2.97 [0.86, 10.27]			2.1.2 YZ	51	58	44	56	3.5%			
015 Ming L	47	52	38	53	1.6%	3.71 [1.24, 11.13]			2019 Ling W 2020 Yall Z	31	26	44	36	2.7%	2.70 [0.91, 0.51] 3.95 [1.24, 12.56]		
015 Ting Z	20	25	14	25	1.3%	3.14 [0.89, 11.06]			Subtotal (95% CI) Total events	82	92	66	92	6.2%	3.29 [1.47, 7.35]		-
016 Lige L	55	60	46	60	1.7%	3.35 [1.12, 9.99]			Heterogeneity: Chi# = 0	10, df = 1	(P = 0.67						
016 Shulan W	59	65	44	65		4.69 [1.75, 12.60]		-	Test for overall effect Z	= 2.90 (P	= 0.004)						
016 Tao L	27	32	19	32		3.69 [1.13, 12.10]			2.1.3 YH								
016 Xiaojing D	36	47	28	49	2.9%	2.45 [1.02, 5.92]			2017 XIaoli Z 2018 Aimin Hu	45	53 50	35		4.7%	2.89 [1.13, 7.43] 4.47 [1.36, 14.76]		
017 NiZ	48	53	42	53		2.51 [0.81, 7.83]			2022 Chuarwong R	40	42	36 34	42	1.4%	4.71 (0.94, 23.67)		
017 Ping D	33	35	25	35	0.6%	6.60 [1.33, 32.84]			Subtotal (95% CI) Total events	121	145	105	145	8.7%	3.66 [1.87, 7.14]		-
17 Rucui Y	36	42	26	38	1.8%	2.77 10.92. 8.341			Heterogeneity, Chi#= 0.	44, df = 2	(P = 0.80	0; = 0%	6				
017 Xiaoli Z	45	53	35	53	2.4%	2.89 [1.13, 7.43]			Test for overall effect Z	= 3.80 (P	= 0.0001)	)					
18 Aimin Hu	46	50	36	50	1.3%	4.47 [1.36, 14.76]		_	2.1.4 SD		37			2.5%			
)18 Huajun L	167	200	138	200		2.27 [1.41, 3.67]			2019 JIII S 2023 Jiali Y	33 56	37	25 46		2.5%	3.30 [0.93, 11.76] 2.96 [1.13, 7.74]		
18 Liwen P	54	60	39	60	1.8%	4.85 [1.79, 13.13]		-	Subtotal (95% CI)	89	100	71	98	7.0%	3.08 [1.43, 6.63]		-
118 Shijian Q	62	76	50	74	4.2%	2.13 [1.00, 4.53]			Total events Heterogeneity: Chi#= 0		(P = 0.89		6				
119 Changsong Z	54	55	47	55	4.2%	9.19 [1.11, 76.22]			Test for overall effect 2	= 2.87 (P	= 0.004)						1
19 Chenhui D	32	39	24	39	1.9%	2.86 [1.01, 8.10]			2.1.5 BT								
119 Gangyi C	32	39	56	39	3.8%	2.29 [1.05, 5.02]			2014 Yalian H 2019 Chenhui D	27	31	22 24		2.3%	4.60 [1.33, 15.88] 2.86 [1.01, 8.10]		
	33	37	25	35	1.3%	3.30 [0.93, 11.76]			2021 Huaizhi L	45	47	37	46	1.4%	6.47 [1.11, 26.91]		
119 Liji S	51	56	44	30 56	1.8%				2021 Jiang H 2022 Meizhen L	32	54	25	54 129 1	9.1%	1.69 (0.79, 3.62) 1.95 (1.03, 3.70)		
119 Ling W			39			2.78 [0.91, 8.51]			2023 Rubruan W	30	33	23	33	1.9%	4.35 [1.07, 17.63]		
19 Sugin W	55	66 47	39	62		2.95 [1.29, 6.74]			Subtotal (95% CI) Total events	277	333	229	338 3	30.7%	2.49 [1.70, 3.66]		•
19 Xiaoze S	42	44		47	1.7%	2.88 [0.93, 8.97]			Heterogeneity. Chi# = 4	12, df= 5	(P = 0.53	0; P= 0%	6				
19 Yangxi F	35		27		2.5%	2.45 [0.95, 6.34]			Testfor overall effect Z	= 4.68 (P	< 0.0000	1)					
19 Zhixiong T	28	33	23	32	1.6%	2.19 [0.64, 7.46]			2.1.6 JH								
20 Dandan P	47	55	35	55	2.3%	3.36 [1.33, 8.50]			2021 Ying L 2023 Duarwang J	46	49		49	2.1%	4.44 [1.15, 17.07] 6.58 [1.39, 31.19]		
20 Wei H	33	47	21	47	2.8%	2.92 [1.25, 6.82]			Subtotal (95% CI)		106				5.31 [1.93, 14.67]		-
120 Yalan H	32	36	22	36	1.1%	5.09 [1.48, 17.53]			Total events Heterogeneity: Chi#= 0	101 14.df=1	(P = 0.71	84					
20 Yali Z	31	36	22	36	1.4%	3.95 [1.24, 12.56]			Test for overall effect Z								
121 Bing Y	49	56	40	56	2.3%	2.80 [1.05, 7.47]			2.1.7 WJHT								
21 Chuanfu Z	42	45	33	45	1.0%	5.09 [1.33, 19.54]	1. State 1.		2018 Shijian Q	62	76		74	8.3%	2.13 (1.00, 4.63)		-
21 Hongye C	68	72	60	72		3.40 [1.04, 11.11]			2021 Hongye C Subtotal (95% CI)	68	72		72	1.7% 1	7.97 [5.93, 54.49] 4.86 [2.72, 8.68]		+
121 Huaizhi L	45	47	37	46	0.7%	5.47 [1.11, 26.91]			Total events Heterogeneity: Chi#= 9	130		05					
121 Jiang H	32	54	25	54	4.6%	1.69 [0.79, 3.62]			Heterogeneity: Chi* = 9 Test for overall effect Z	92, df = 1 = 5.34 dP	(P = 0.00 < 0.0000	(2); P= 9 1)	0%				
)21 Jinfeng S	33	40	27	40	2.1%	2.27 [0.79, 6.49]			2.1.8 YYT								
021 Xiaomei D	71	75	61	73		3.49 [1.07, 11.39]			2017 Rucui Y	36	42	26		3.5%	2.77 (0.92, 8.34)		
021 Ying L	46	49	38	49	1.0%	4.44 [1.15, 17.07]		_	2022 Yan C Subtotal (95% CI)	45	48 90	37	48 86	2.1%	4.46 [1.16, 17.18] 3.40 [1.46, 7.94]		-
122 An Z	50	53	42	53	1.1%	4.37 [1.14, 16.69]			Total events	81		63		9.9%	Stan Lines, stand		
22 Chuanyong R	40	42	34	42	0.7%	4.71 [0.94, 23.67]			Heterogeneity: Chi#= 0 Test for overall effect Z			0; I* = 0%	6				
22 Haitao X	53	60	40	60	2.1%	3.79 [1.46, 9.82]				- 2.03 (-	- 0.000)						
122 LI T	37	43	30	41	1.9%	2.26 [0.75, 6.83]			2.1.9 BYTH 2018 Liwen P	54	60	39	60	3.6%	4.85 (1.79, 13, 13)		
122 Meizhen L	111	129	98	129	6.2%	1.95 [1.03, 3.70]			2021 Bing Y	49	56	40	58	4.5%	2.80 [1.05, 7.47]		
22 Ping W	55	60	47	60	1.8%	3.04 [1.01, 9.16]			Subtotal (95% CI) Total events	103	116	79		7.9%	3.70 [1.84, 7.41]		-
22 Yan C	45	48	37	48	1.0%	4.46 [1.16, 17.18]			Heterogeneity: Chi# = 0.	59, df = 1	(P = 0.44	); P = 0%	6				1
22 Yu Z	63	65	52	61	0.7%	5.45 [1.13, 26.35]			Test for overall effect Z	= 3.69 (P	= 0.0002	)					1
23 Duanyang J	55	57	46	57	0.7%	6.58 [1.39, 31.19]			2.1.10 GJ								
23 Jiali Y	56	63	46	63	2.3%	2.96 [1.13, 7.74]			2017 Ni Z 2020 VWi H	48	53 47	21	47	3.5%	2.51 [0.81, 7.83] 2.92 [1.25, 6.02]		
23 Rukuan W	30	33	23	33	0.9%	4.35 [1.07, 17.63]			Subtotal (95% CI)	81	100	63		9.1%	2.76 [1.40, 5.46]		-
23 Xue F	45	48	42	53		3.93 [1.02, 15.06]	-	-	Total events Heterogeneity: Chi# = 0	04. df = 1	(P = 0.84		6				1
ibtotal (95% CI)		2771		2762	100.0%	3.12 [2.70, 3.60]	•		Test for overall effect Z	= 2.92 (P	= 0.0030						1
tal events	2438		1960						2.1.11 JB								1
eterogeneity: Chi <sup>2</sup> = 2				= 0%					2015 Jialing Y	39	43			2.2%	5.78 [1.74, 19.19]		
st for overall effect Z	= 15.45	(P < 0.00	0001)						2019 Gangyi C Subtotal (95% CI)	67	122	56			2.29 [1.05, 5.02] 3.09 [1.62, 5.89]		-
									Total events Heterogeneity: Chi# = 1	106 60 df= 1	(P = 0.34	83					
tal (95% CI)		2771		2762	100.0%	3.12 [2.70, 3.60]	•		Test for overall effect Z	= 3.42 (P	= 0.00060	) V G = 36.	~				1
otal events	2438		1960						Total (95% CD		1382		379 44	00.0%	3.33 [2.72, 4.06]		•
eterogeneity: Chi <sup>2</sup> = 2				= 0%			0.01 0.1 1 10	100	Total events	1209		944			and feases should		· ·
st for overall effect 2							Favours (experimental) Favours (cont		Heterogeneity: Chi#= 2 Test for overall effect Z	2.88, df=	25 (P = 0. P < 0.000	58); P = (	0%			0.01 0.1	10
st for subaroup diffe	rences: N	lot appli	cable				avous texperimental in avous from		Test for subaroup differ	ences: Ci	1/* = 6.64.	df= 10 (	P = 0.76	6). I* = 0'	%.	Favours (experimenta	I] Favours [control]
GURE 3																	
fficacy forest	t nlot	& ef	ficacy	nre	escrint	tion forest r	lot										
neacy iores	r piot	0 81	neacy	pre	scrip	cion iorest p	NOC.										

order of their visits (Rong Y, 2019; Suqin W, 2019), and were assessed as high risk. The remaining studies did not specify the specific method of allocation and were assessed as unknown risk. One study used the envelope method for allocation concealment

(Yalian H, 2014), which was assessed as low risk. The remaining studies did not mention allocation concealment and were assessed as unknown risk. One study mentioned single-blinding and was assessed as high risk, while the remaining studies did not



mention blinding and were assessed as unknown risk. Four studies had dropouts with corresponding explanations, and were assessed as high risk. The remaining studies had complete outcome data and were assessed as low risk. All studies were not registered and selective reporting could not be judged and was evaluated as unknown risk. No studies were found to have other biases and were assessed as low risk (Figure 2).

## 3.4 Primary outcomes

51 studies were included in the analysis of the clinical efficacy outcome measure. The results showed that the clinical efficacy of traditional Chinese medicine decoctions as an adjunctive treatment for diabetic nephropathy was higher than that of the control group (OR = 3.12, 95% CI [2.70, 3.60],  $I^2 = 0\%$ , p < 0.00001). Subgroup analysis based on the composition of the traditional Chinese medicine decoctions showed that the GF group had the most significant improvement in clinical efficacy compared to the control group (OR = 7.88, 95% CI [1.96, 31.68],  $I^2 = 0\%$ , p = 0.004), while the WJHT group had the least significant improvement (OR = 2.46, 95% CI [1.31, 4.64],  $I^2 = 0\%$ , p = 0.005) (Figure 3).

A total of 28 studies were included in the analysis of the adverse event incidence outcome measure. For a further specific adverse reaction reports please check the Supplementary Table S9. The results showed that there was no statistically significant difference in the occurrence of adverse events between the intervention group and the control group for the treatment of diabetic nephropathy (OR = 0.94, 95% CI [0.60, 1.48],  $I^2 = 0\%$ , p = 0.94). Sensitivity analysis did not reveal any significant sources of sensitivity. Subgroup analysis based on the composition of the traditional Chinese medicine decoctions showed that the WJHT group had the most significant reduction in the occurrence of adverse events compared to the control group (OR = 0.48, 95% CI [0.11, 1.99],  $I^2 = 0\%$ , p = 0.76), while the BT group had the least significant reduction (OR = 0.85, 95% CI [0.31, 2.34],  $I^2 = 0\%$ , p = 0.005) (Figure 4).

## 3.5 Secondary outcomes

58 studies were included in the analysis of the SCR outcome measure. The results showed that traditional Chinese medicine decoctions as an adjunctive treatment were superior to the control group in reducing SCR in patients with diabetic nephropathy (MD = -18.04, 95% CI [-21.42, -14.66],  $I^2 = 100\%$ , p < 0.00001). Subgroup analysis based on the composition of the traditional Chinese medicine decoctions showed that there was no statistically significant difference in the reduction of SCR between the intervention and control groups in the GF group, YZ group, YH group, and JB group (p = 0.33, p = 0.38, p = 0.08, p = 0.45, respectively). The most significant reduction in SCR compared to the control group was observed in the BYTH group (SMD = -5.78, 95% CI [-9.11, -2.44],  $I^2 = 99\%$ , p = 0.0007), while the least significant reduction was observed in the JB group (SMD = -0.91, 95% CI [-3.31, 1.48],  $I^2 = 99\%$ , p = 0.45) (Figure 5).

27 studies were included in the analysis of the UAER outcome measure. The results showed that traditional Chinese medicine decoctions as an adjunctive treatment were superior to the control group in reducing UAER in patients with diabetic nephropathy (MD = -36.87, 95% CI [-47.17, -26.56],  $I^2 = 100\%$ , p < 0.00001).

tudy or Subgroup	Exper	imental SD	Total	Co Mean	ntrol SD	Total	Weight	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% Cl	Experimental Control Std. Mean Difference Std. Mean Difference Std. Mean Difference Std. Mean SD Total Mean SD Total Weight M. Random, 595 Cl M. Random 595 Cl
013 Yi S	-20.54	2.16	52	-4.79	1.08	52	1.8%	-15.75 [-16.41, -15.09]	*	2014 Angui J -2.09 3.67 30 -2.23 3.11 30 3.2% 0.0450.47.055
014 Angui J	-2.09	3.67	30	-2.23	3.11	30	1.8%	0.14 [-1.58, 1.86]	+	2014 Liping T -79.9 5.29 39 -48.12 3.62 39 3.0% -6.94 (-8.14, -6.74) Subtotal (95% Cb) 69 69 6.2% -3.43 (-10.27, 3.41)
14 Liping T	-79.9	5.29	39	-48.12	3.62	39	1.8%	-31.78 [-33.79, -29.77]	-	Histerogeneity: Tau# = 24.16; Ch# = 109.98; df = 1 (P < 0.50001); # = 99% Test for overall effect Z = 0.99 (P = 0.33)
14 Yalian H	-15.47	0.91	31	-12.44	6.91	37	1.8%	-3.03 [-5.28, -0.78]	-	
15 Bailong C	-120.26	1.74	41	-84.66	1.25	41	1.8%	-35.60 [-36.26, -34.94]		1.3.2 YZ 2019 Ling W -40.83 6.68 56 -25.04 4.07 56 3.2% -2.84 [3.36,-2.31]
15 Beide S	-21.65	6.99	89	-6.9	8.08	89	1.8%	-14.75 [-16.97, -12.53]	-	2020 Yali Z -16.03 1.73 36 -16.37 1.81 36 3.2% 0.19[-0.27, 0.65]
15 Jialing Y	-3.1	1.3	43	-3.4	0.4	43	1.8%	0.30 [-0.11, 0.71]		Subtotal (95% C) 92 92 6.4% .1.32 [.4.28, 1.64]
15 Jianmin Y	-23.11	0.9	48	-4.69	7.3	47	1.8%	-18.42 [-20.52, -16.32]	-	Test for overall effect Z = 0.87 (P = 0.26)
015 Jingjing H	-20	1.3	50	-18.8	0.5	50	1.8%	-1.20 [-1.59, -0.81]	-	13378
015 Ting Z	-20.73	3.22	25	-5.38	2.56	25	1.8%	-15.35 [-16.96, -13.74]		2017 Xiac6 Z -150.7 11.8 53 -91.9 13.8 53 3.1% -4.55[-5.28,-3.02]
16 Lige L	-7.94	2.39	60	-3.21	0.18	60	1.8%	-4.73 [-5.34, -4.12]		2018 Almin Hu -3.49 1.01 50 -4.27 4.28 50 3.2% 0.25 0.14, 0.54 2022 Chuaryong R -18.85 1.38 42 -10.92 0.38 42 2.9% -7.76 0.94, 4.48
016 Shulan W	-148.89	26.94	65	-70.74	10.97	65	1.7%	-78.15 [-85.22, -71.08]		Subtolal (95% CI) 145 145 9.3% -3.99 [-8.50, 0.52]
016 Tao L	-1.78	1.14	32	-4.22	0.65	32	1.8%	2.44 [1.99, 2.89]		Heterogeneity: Tau# = 15.69; Ch# = 233.84; df = 2 (P < 0.00001); # = 99% Test for overall effect Z = 1.73 (P = 0.08)
017 Ping D	-8.43	0.64	35	-8.16	1.65	35	1.8%	-0.27 [-0.86, 0.32]		
17 Xiaoli Z	-150.7	11.8	53	-91.9	13.8	53	1.7%	-58.80 [-63.69, -53.91]	-	1.3.4 SD 2023 Jibil Y -17.95 1.07 63 -13.52 1.37 63 3.2% -2.69 [-3.17, -2.20]
018 Aimin Hu	-3.49	1.01	50	-4.27	4.28	50	1.8%	0.78 [-0.44, 2.00]		Subtotal (95% CI) 63 63 3.2% -2.69 [-3.17, -2.20]
018 Huajun L	-60.9	10.19	200	-35.22	8.96	200	1.8%	-25.68 [-27.56, -23.80]	-	Heterogeneity Not applicable Test for overall effect Z = 10.05 (P = 0.00001)
018 Liwen P	-8.92	8.31	60	-5.53	3	60	1.8%	-3.39 [-5.63, -1.15]	-	
018 Min Z	-22.02	1.58	36	-15.72	0.77	36	1.8%	-6.30 [-6.87, -5.73]		13.5.04 2021 Ying40.16 4.08 49 -34.53 4.16 49 3.2% -2.5913.562.40
018 Shijian Q	-15.04	0.63	76	-11.18	1.1	74	1.8%	-3.86 [-4.15, -3.57]		2023 Duaryang J 42.69 5.28 57 -26.85 4.21 57 3.2% -3.291-3.86,-2.73
018 Xiaoyi Z	-45.79	11	40	-22.4	7.11	40	1.8%	-23.39 [-27.45, -19.33]	-	Subtotal (95% CB 506 506 506 506 507 -3.14 [-3.55, -2.74]
019 Changsong Z	-57.5	7.3	55	-44.4	5.8	55	1.8%	-13.10 [-15.56, -10.64]	-	Test for overall effect Z = 15.13 (P < 0.0001)
019 Chenhui D	-4.43	0.64	39	-4.75	0.26	39	1.8%	0.32 [0.10, 0.54]		1368T
019 Gangyi C	-30	0	40	-6	0	39		Not estimable		2014 Yalian H -15.47 0.91 31 -12.44 0.91 37 3.2% -0.581/1.07,-0.091
019 Ling W	-136.08	14.67	79	-107.78	11.51	79	1.8%	-28.30 [-32.41, -24.19]	~	2019 Chenhui D -4.43 0.64 39 -4.75 0.26 39 3.2% 0.65 [0.19,1.10]
019 Rong Y	-40.83	6.68	56	-25.04	4.07	56	1.8%	-15.79 [-17.84, -13.74]	-	2021 Husizhi L -58.08 4.33 47 -44.79 3.36 46 3.2% -3.401-4.04,-2.75
019 Sugin W	-62.38	44.08	33	-31.91	8.46	33	1.3%	-30.47 [-45.78, -15.16]		2021 Jiang H -11.33 4.56 54 -0.50 3.55 54 3.2% -0.67 1.06, -0.20 - 2022 Melzhen L -44,41 2.38 129 -26.61 1.15 129 3.1% -0.50 [-1.0.6, -0.63]
019 Xiaoze S	-24.93	3.11	66	-14.37	3.46	62	1.8%	-10.56 [-11.70, -9.42]		2022 Yu Z -27.9 4.98 65 -22.30 3.81 61 3.2% -1.23 [1.61, -0.95] -
019 Yangxia L	-131.2	12.29	47	-99.73	20.67	47	1.7%	-31.47 [-38.35, -24.59]		202330n Y -7.18 2.58 39 -0.64 3.02 39 3.2% -2.31 2.88 -1.73 - 202330a F -32.83 3.35 48 -25.58 1.42 53 3.2% -2.85 3.41 -2.28 -
019 Zhixiong T	-151.02	22.02	40	-110.13	17.24	40	1.6%	-40.89 [-49.56, -32.22]		Subtotal (95% Ct) 512 518 28.4% -3.09 [-4.69, -1.49]
020 Dandan P	-15.87	8.73	33	4.75	0.86	32	1.8%	-20.62 [-23.61, -17.63]	-	Heterogeneity Tau# = 5.87, Ch# = 649.00, df = 8 (# < 0.00001); I# = 99% Test for overall effect Z = 3.79 (# = 0.0001)
020 Wei H	-12.9	1.49	55	-4.75	0.43	55	1.8%	-8.15 [-8.56, -7.74]		137WAIT
020 Xinxin P	-12.98	1.57	47	-5.14	1.55	47	1.8%	-7.84 [-8.47, -7.21]		
020 Yalan H	-95	42.86	36	-84.73	41.62	34	1.1%	-10.27 [-30.06, 9.52]		2018 Shijian Q -15.04 0.63 76 -11.18 1.1 74 3.2% -4.30 4.89,-3.71]
020 Yali Z	-33.23	6.19	36	-15.66	2.82	36	1.8%	-17.57 [-19.79, -15.35]	-	2021 Hongye C -16.2 2.36 72 -7.12 1.68 72 3.2% -4.41 [-5.02, -3.03] Substat (35% C) 173 171 9.3% -4.45 [-4.65, -4.65]
021 Bing Y	-16.03	1.73	36	-16.37	1.81	36	1.8%	0.34 [-0.48, 1.16]		Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.75; df = 2 dP = 0.42; P = 0%
021 Chuanfu Z	-19.82	2.21	56	-13.02	1.69	56	1.8%	-6.80 [-7.53, -6.07]		Test for overall effect Z = 21.02 (P = 0.00001)
021 Cuiging Z	-124.71	3.25	45	-3.59	1.53	45	1.8%	-121.12 [-122.17, -120.07]		1.3.8 YYT
021 Hongye C	-48.02	2.63	60	-28.41	2.02	60	1.8%	-19.61 [-20.45, -18.77]		2022 Yan C -11.54 3.06 40 -3.62 2.01 40 3.2% -2.67 [-3.23, -2.12] Subtotal (95% Cb 40 40 3.2% -2.67 [-3.23, -2.12]
021 Huaizhi L	-16.2	2.36	72	-7.12	1.68	72	1.8%	-9.08 [-9.75, -8.41]		Historopennity: Not applicable
021 Jiang H	-58.08	4.33	47	-44.79	3.36	46	1.8%	-13.29 [-14.86, -11.72]		Test for overall effect Z = 9.43 (P × 0.00001)
021 Jinfeng S	-11.33	4.56	54	-8.58	3.55	54	1.8%	-2.75 [-4.29, -1.21]	-	13.9 GJ 2020 Wei H -12.98 1.57 47 -514 1.55 47 3.1% -4.981-5.82 -4.19
021 Xiaomei D	-84.51	11.01	40	-34.1	11.23	40	1.7%	-50.41 [-55.28, -45.54]	-	2020 Wei H -12.90 1.57 47 -5.14 1.55 47 2.1% -4.90 [-5.92, -4.15]
021 Ying L	-27.78	1.82	75	-19.57	1.29	73	1.8%	-8.21 [-8.72, -7.70]		Heterogeneity. Not applicable
022 An Z	-48.16	4.88	49	-34.53	4.16	49	1.8%	-13.63 [-15.43, -11.83]	-	Test for overall effect Z = 11.73 (P < 0.00001)
022 Chuanyong R	-59.57	4.75	53	-43.42	2.82	53	1.8%	-16.15 [-17.64, -14.66]	•	1.3.10 JB
022 Haitao X	-18.85	1.38	42	-10.92	0.38	42	1.8%	-7.93 [-8.36, -7.50]		2015 Jialing Y -3.1 1.3 43 -3.4 0.4 43 3.2% 0.31 [-0.12, 0.73] 2019 Gangel C -126.08 14.67 79 -107.78 11.51 79 3.2% -2.14 [-2.53, -1.74]
022 Lei Z	-36.38	26.68	60	-22.04	13.46	60	1.7%	-14.34 [-21.90, -6.78]		Subtotal (95% CB) 122 122 6.4% -0.91[-3.31, 1.48]
022 LI T	-40.62	0.57	51	-31.09	0.69	51	1.8%	-9.53 [-9.78, -9.28]		Histerogeneity: Tau" = 2.95; Chi" = 68.55; df = 1. (P < 0.00601); P = 99% Test for overall effect Z = 0.75 (P = 0.45)
022 Meizhen L	-65.44	4.99	43	-21.42	3.5	41	1.8%	-44.02 [-45.86, -42.18]		13.11070
022 Ping W	-44.41	2.38	129	-26.61	1.15	129	1.8%	-17.80 [-18.26, -17.34]		2018 Liwen P - 8.92 8.31 60 -5.53 3 60 3.2% -0.54 [-0.90, -0.17] -
022 Yan C	-139.91	11.3	60	-105.47	8.64	60	1.8%	-34.44 [-38.04, -30.84]	-	2018 Mm 2 -22.02 1.58 36 -15.72 6.77 36 3.1% -5.01 5.58, -4.05 2021 Bing Y -19.92 2.21 56 -13.02 1.69 56 3.2% -3.43 54.02, -2.84
022 Yu Z	-11.54	3.06	48	-3.62	2.81	48	1.8%	-7.92 [-9.10, -6.74]	-	2022 Lei Z -40.62 0.57 51 -31.09 0.69 51 2.5% -14.951-17.07 -12.821
023 Duanyang J	-27.9	4.98	65	-22.38	3.81	61	1.8%	-5.52 [-7.06, -3.98]	-	Subtotal (95% CB 203 203 12.0% -5.781-9.11, -2.44)
023 Jiali Y	-42.69	5.28	57	-26.85	4.21	57	1.8%	-15.84 [-17.59, -14.09]	-	Heteropenetity. Tau# = 11.32; Ch# = 264.34, df = 3 (P < 0.00001); # = 99% Test for overall effect Z = 3.40 (P = 0.0007)
023 Rubruan W	-95.12	30.29	33	-45.66	42.8	33	1.2%	-49.46 [-67.35, -31.57]		13 12 IV
023 Xin Y	-17.95	1.87	63	-13.52	1.37	63	1.8%	-4.43 [-5.00, -3.86]		2015.Jinging H -20 1.3 50 -18.8 0.5 50 3.2% -1.21 [+1.64, -0.78] -
023 Xue F	-7.18	2.58	39	-0.64	3.02	39	1.8%	-6.54 [-7.79, -5.29]	-	2019 Yangsis L -151.02 22.02 40 -110.13 17.24 40 3.2% -2.05 [-2.59, -1.50] * Subtotal (95% CD 90 90 6.4% -1.61 [-2.43, -0.79] *
									2.5	Subtotal (95% CB) 90 90 6.4% -1.61 [-2.43, -6.79] Heteropeneity: Tau*= 0.29; Chi*= 5.62, df = 1.0? = 0.02; (*= 02%
otal (95% CI)			3094			3080	100.0%	-18.04 [-21.42, -14.66]	•	Test for overall effect Z = 3.84 (P = 0.0001)
leterogeneity: Tau <sup>a</sup> =	164.64; CI	ni*= 718	375.85.	df = 56 (F	e < 0.001	001); I <sup>a</sup>	= 100%		-100 -50 0 50 100	Total (95% CI) 1670 1674 100.0% -3.30 (-4.03, -2.57)
est for overall effect:										Heterogeneity: Tau" = 4.32; Chi" = 1759.45; df = 31 (P < 0.00001); P = 99%
			0						Favours [experimental] Favours [control]	Test for subarous differences: Ch <sup>ar</sup> = 02.01. df = 11.0P < 0.00001). P = 06.7% Favours [experimental] Favours [control]
GURE 5										
							st pla			

Subgroup analysis based on the composition of the traditional Chinese medicine decoctions showed that all subgroups of traditional Chinese medicine were able to significantly reduce UAER compared to the control group (p < 0.001). The most significant reduction in UAER compared to the control group was observed in the JH group (SMD = -6.78, 95% CI [-7.82, -5.73], p < 0.00001), while the least significant reduction was observed in the GF group (SMD = -1.49, 95% CI [-2.00, -0.99], p < 0.00001) (Figure 6).

40 studies were included in the analysis of the BUN outcome measure. The results showed that traditional Chinese medicine decoctions as an adjunctive treatment were superior to the control group in reducing BUN levels in patients with diabetic nephropathy (MD = -1.31, 95% CI [-1.53, -1.10],  $I^2$  = 100%, p < 0.00001). Subgroup analysis based on the composition of the traditional Chinese medicine decoctions showed that there was no statistically significant difference in the reduction of BUN levels between the GF group, YZ group, YH group, and the control group (p = 0.22, p = 0.05, p = 0.14). The most significant reduction in BUN levels compared to the control group was observed in the HY group (SMD = -11.06, 95% CI [-1.2.87, -9.25], p < 0.00001), while the least significant reduction was observed in the GJ group (SMD = -0.70, 95% CI [-1.12, -0.29], p = 0.0009) (Figure 7).

36 studies were included in the analysis of the 24 h-utp outcome measure. The results showed that traditional Chinese medicine

decoctions as an adjunctive treatment were superior to the control group in reducing 24 h-utp levels in patients with diabetic nephropathy (MD = -0.30, 95% CI [-0.35, -0.25],  $I^2$  = 100%, p < 0.00001). Subgroup analysis based on the composition of the traditional Chinese medicine decoctions showed that there was no statistically significant difference in the reduction of 24 h-utp levels between the YZ group, YYT group, BYTH group, and the control group (p = 0.10, p = 0.24, p = 0.27). The most significant reduction in 24 h-utp levels compared to the control group was observed in the WJHT group (SMD = -6.19, 95% CI [-7.57, -4.81], p < 0.00001), while the least significant reduction was observed in the YZ group (SMD = -0.81, 95% CI [-1.75, 0.14],  $I^2 = 89\%$ , p = 0.10) (Figure 8).

41 studies were included in the analysis of the FPG outcome measure. The results showed that traditional Chinese medicine decoctions as an adjunctive treatment were superior to the control group in reducing FPG levels in patients with diabetic nephropathy (MD = -0.64, 95% CI [-0.79, -0.49],  $I^2 = 100\%$ , p < 0.00001). Subgroup analysis based on the composition of the traditional Chinese medicine decoctions showed that there was no statistically significant difference in the reduction of FPG levels between the GF group, YZ group, YH group, and HY group compared to the control group (p = 0.26, p = 0.72, p = 0.08, p = 0.23). The most significant reduction in FPG levels

Study or Subgroup 2014 Liping T 2015 Beide S	Mean									Study or Subgroup	Mean		al Mean		Total V		IV, Random, 95% CI	IV, Randor	
	20.00			Mean		Total		IV, Random, 95% Cl	IV, Random, 95% Cl	4.1.1 GF 2014 Liping T	-73.32	0.4 3	9 .66 71	6.19	39	6.4%	-1.49 [-2.00, -0.99]	-	
2015 Beide S	-73.32		39	-66.71		39	3.7%	-6.61 [-8.56, -4.66]		Subtotal (95% CI)		3	19	0.10	39	6.4%	-1.49 [-2.00, -0.99]	•	
		40.06	89		24.18	89	3.6%	-51.84 [-61.56, -42.12]		Heterogeneity: Not ap Test for overall effect.									
2015 Jialing Y		4.5	43	-19.8		43	3.7%	-24.90 [-26.59, -23.21]			7 = 2'\ a (b i	0.00001	9						
2015 Jianmin Y	-58.28		48	-34.45		47	3.7%	-23.83 [-27.94, -19.72]	· ·	4.1.2 YZ					56			-	
2016 Lige L	-261.06	22.42	60	-125.19	18.41	60	3.7%	-135.87 [-143.21, -128.53]	÷	2019 Ling W Subtotal (95% CD	-71.29 11		6 -32.18	7.26	56	6.3%	-3.93 [-4.57, -3.29] -3.93 [-4.57, -3.29]	•	
2017 Ni Z	-64.49	11.18	53	-30.1	19.77	53	3.7%	-34.39 [-40.50, -28.28]	+	Heterogeneity: Not ap									
2018 Liwen P	-91.34	9.98	60	-59.62	1.87	60	3.7%	-31.72 [-34.29, -29.15]	•	Test for overall effect.	Z = 12.00 (P	< 0.0000	01)						
2018 Min Z	-77.29	3.55	36	-70.73	4.12	36	3.7%	-6.56 [-8.34, -4.78]	•	4.1.3 YH								~	
2018 Xiaoyi Z	-85.57	0.25	40	-19.13	1.15	40	3.7%	-66.44 [-66.80, -66.08]		2022 Chuanyong R Subtotal (95% CI)	-61.18 9		2 -42.09	6.67	42	6.4% 6.4%	-2.35 [-2.91, -1.79] -2.35 [-2.91, -1.79]	Ŧ	
2019 Chenhui D	-84.78	13.29	39	-60.32	12.04	39	3.7%	-24.46 [-30.09, -18.83]	-	Heterogeneity: Not ap	plicable		12		42	0.41	-229 [-229 ], -129 ]		
2019 Ling W	-71.29	11.95	56	-32.18	7.26	56	3.7%	-39.11 [-42.77, -35.45]	-	Test for overall effect.	Z = 8.20 (P	< 0.00001	1)						
2019 Sugin W	-57.17	5.67	66	-25.75	4 39	62	3.7%	-31.42[-33.17, -29.67]	•	4.1.4 JH									
2019 Zhixiona T	-53.67			-31.21			3.7%	-22.46 [-27.31, -17.61]	-	2021 Ying L	-93.8 4		9 -68.63	1.91		5.8%	-6.78 [-7.82, -5.73]	-	
2020 Dandan P	-78.01			-58.11		55	3.7%	-19.90 [-23.76, -16.04]	-	Subtotal (95% CI) Heterogeneity: Not ap	nlicable	-4	9		49	5.8%	-6.78 [-7.82, -5.73]	-	
2020 Wei H	-56.63		47	-33.9			3.7%	-22.73 [-26.38, -19.08]	-	Test for overall effect.	Z = 12.70 (P	< 0.0000	01)						
2020 Yalan H	-53.13			-21.32		36	3.7%	-31.81 [-35.53, -28.09]	-	4.1.5 BT									
2021 Bing Y	-89.88			-17.63		56	3.7%	-72.25 [-76.38, -68.12]	-	2016 Xiaojing D	-84.78 13			12.04		6.4%	-1.91 [-2.45, -1.37]	-	
2021 Bing 7 2021 Chuanfu Z			45	4.82		50 45	3.7%			2021 Jiang H 2022 Meizhen L	-90.14 10		4 -48.85		54		-4.81 [-5.57, -4.06] -4.01 [-4.43, -3.58]	-	
	-79.83							-84.65 [-86.47, -82.83]		2022 Meizhen L 2022 Yu Z	-31.25 2			4.94			-4.01 [-4.43, -3.58]	-	
2021 Hongye C		6.12		-16.62			3.7%	-22.38 [-24.05, -20.71]		2023 Xin Y	-73 21		9 -36.85		39		-1.67 [-2.19, -1.15]	· -	
2021 Jiang H	-90.14			-48.85		54	3.7%	-41.29 [-44.50, -38.08]		Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> =	2.00 ChP=	32			322  P= 969		-3.38 [-4.64, -2.11]	-	
2021 Jinfeng S	-102.08			-33.06		40	3.7%	-69.02 [-74.78, -63.26]		Test for overall effect.									
2021 Ying L		4.85		-68.63		49	3.7%	-25.17 [-26.63, -23.71]		4.1.6 WJHT									
2022 Chuanyong R	-61.18			-42.09			3.7%	-19.09 [-22.54, -15.64]	•	2021 Hongye C	-39 6		2 -16.62	3.85	72	6.3%	-4.35 [-4.96, -3.75]	+	
2022 Meizhen L				-24.51			3.7%	-6.74 [-7.15, -6.33]		Subtotal (95% CI) Heterogeneity: Not ap	alicabla	7	2		72	6.3%	-4.35 [-4.96, -3.75]	•	
2022 Ping W	-39.84	0.42	60	-16.32	1.11	60	3.7%	-23.52 [-23.82, -23.22]	•	Test for overall effect.		< 0.0000	01)						
2022 Yu Z	-55.99	5.22	65	-32.73	4.94	61	3.7%	-23.26 [-25.03, -21.49]		4.1.7 GJ									
2023 Xin Y	-73	21.08	39	-36.85	21.85	39	3.6%	-36.15 [-45.68, -26.62]	-	2017 NIZ	-64.49 11	.18 5	3 -30.1	19.77	53	6.4%	-2.13 [-2.61, -1.65]	-	
										2020 Wei H	-56.63 11		7 -33.9	5.95		6.4%	-2.50 [-3.04, -1.96]	-	
Total (95% CI)			1451			1441	100.0%	-36.87 [-47.17, -26.56]	•	Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> =	0.00 ChF=	10 1.02 df:		31): P= 29		12.8%	-2.29 [-2.65, -1.93]	•	
Heterogeneity: Tau <sup>2</sup> =	741.30; C	hi <sup>2</sup> = 584	179.45,	df = 26 (	P < 0.00	001); P:	= 100%	-		Test for overall effect.									
Test for overall effect 2	Z = 7.01 (8	< 0.000	001)						-100 -50 0 50 100	4.1.8 JB									
									Favours [experimental] Favours [control]	2015 Jialing Y	-44.7			3.4			-6.19 [-7.22, -5.15]	-	
										Subtotal (95% CI) Heterogeneity: Not ap	aliaabla	4	3		43	5.8%	-6.19 [-7.22, -5.15]	•	
										Test for overall effect.		< 0.0000	01)						
										4.1.9 BYTH									
										2018 Liwen P	-91.34 9	.98 6	0 -59.62	1.87	60	6.3%	-4.39 [-5.06, -3.72]	+	
										2018 Min Z	-77.29 3		6 -70.73	4.12		6.4% 6.0%	-1.69 [-2.23, -1.15]	-	
										2021 Bing Y Subtotal (95% CI)	-89.88 2	15	6 -17.63	15.5	152		-6.44 [-7.37, -5.50] -4.15 [-6.80, -1.50]	-	
										Heterogeneity: Tau <sup>a</sup> =		87.36, dt		0.00001);1				10000	
										Test for overall effect.	Z = 3.07 (P =	= 0.002)							
										Total (95% CI)		87			875 1		-3.65 [-4.39, -2.91]	•	2
										Heterogeneity: Tau <sup>2</sup> = Test for overall effect				< 0.00001	); l <sup>a</sup> = 98	3%		-10 -5 0	5
										Test for subaroup diffe				P < 0.000	01). (*=	95.3%		Favours (experimental)	Favours (control)
IGURE 6																			
								forest plot.											

	Expe				ontrol			Mean Difference	Mean Difference	Study or Subgroup Mean SD Total Mean SD Total Weight N. Random, 95% Cl N. Random, 95% Cl
tudy or Subgroup								IV, Random, 95% Cl	IV, Random, 95% Cl	2014 Angui J -0.32 0.09 30 -0.25 0.29 30 4.0% -0.33 [-0.84, 0.18] 2014 Liping T -5.16 1.11 39 -1.91 0.78 39 3.9% -3.35 [-4.05, -2.66]
014 Angui J	-0.32		30	-0.25		30	2.8%	-0.07 [-0.18, 0.04]	1	Submital (95% CI) 69 69 69 8.0% 1.83 [-4.80, 1.13] Heteropereity Tau" = 4.47, Chi* = 46.00, df = 1 (9 = 0.00001); #= 98%
14 Liping T	-5.16	1.11	39	-1.91	0.78	39	2.5%	-3.25 [-3.68, -2.82]		Test for overall effect $Z = 1.21$ (P = 0.22)
15 Beide S	-2.12	0.22	89	-0.33	0.1	89	2.8%	-1.79 [-1.84, -1.74]	-	5.1.2 VZ 2019 Ling W -5.79 0.71 56 -3.79 0.40 56 4.0% -3.20 (-3.85,-2.70)
15 Jialing Y	-1.47	0.41	43	-0.84	0.58	43	2.7%	-0.63 [-0.84, -0.42]	~	2019 Urg 147 - 5-79 071 56 -579 046 55 4076 - 4.01519, 270 2020 Yuki 2 - 1.02 0.2 36 -0.06 0.06 36 41% - 1.04153, 0.59] Subtrata (95% Cl) 92 92 82 8.1% - 2.15[4,35, 0.04]
15 Jingjing H	-1.3	0	50	-1	0	50		Not estimable		Hetersperety Tau" = 2.42, Chi" = 32.85, df = 1 (P < 0.00001), i" = 37% Test for overall affect Z = 1.82 (P = 0.05)
17 Xiaoli Z	-3.59	0.12	53	-1.78	0.65	53	2.7%	-1.81 [-1.99, -1.63]	-	
18 Aimin Hu	-0.6	0.33	50	-0.32	0.4	50	2.8%	-0.28 [-0.42, -0.14]	-	5.1.3 KD 2022 Julis Y -1.3 0.13 63 -0.67 0.07 63 3.9% -6.00[6.03,-5.17]
18 Huajun L	-3.8	0.88	200	-2.79	0.55	200	2.8%	-1.01 [-1.15, -0.87]	-	Heterogeneity: Not applicable
18 Liwen P	-0.34	0.05	60	-0.05	0.95	60	2.7%	-0.29 [-0.53, -0.05]	~	Testfor overall effect Z = 14.17 (P < 0.00001)
18 Min Z	-1.56	0.7	36	-0.81	0.93	36	2.6%	-0.75 [-1.13, -0.37]		5.1.4 YM 2017 Xiaoli Z -3.59 0.12 53 -1.78 0.85 53 4.0% -3.84 [-4.50,-3.19]
18 Shijian Q	-2.9	0.43	76	-2.39	0.42	74	2.8%	-0.51 [-0.65, -0.37]	-	2023 Duanyang J -0.6 0.33 50 -0.32 0.4 50 4.1% -0.76 [-1.16, -0.35] Subtotal (95% Cl) 103 103 8.1% -2.29 [-5.32, 0.73]
19 Changsong Z		1.2	55	-1.8		55	2.6%	-2.30 [-2.64, -1.96]		Heterogeneity: Tau# = 4.69, Ch# = 62.22, df = 1 (P = 0.00001); # = 60% Test for overall effect Z = 1.49 (P = 0.14)
19 Chenhui D	0.19		39		0.09	39	2.8%	0.19 [0.16, 0.22]		5.15 JH
019 Gangyi C	-2		40	-0.8		39	2.8%	-1.20 [-1.33, -1.07]	-	2021 Ying L -3.07 1.14 49 -1.69 0.96 49 4.1% -1.30[+1.74,-0.6] 2023 Duanyang J -2.84 0.45 57 -1.61 0.34 57 4.0% -3.06[-3.61,-2.52]
19 Ling W	-7.02			-5.04		79	2.7%	-1.98 [-2.22, -1.74]		Subtotal (95% CI) 105 106 8.1% -2.17 [-3.90, -0.44] Heteropenety: Tau? = 1.49; Ch? = 24.41; d? = 1.0? < 0.00001); P = 90%
19 Sugin W	-5.79			-3.79		56	2.7%	-2.00 [-2.22, -1.78]		Test for overall effect Z = 2.46 (P = 0.01)
19 Xiaoze S	-1.04			-0.27		62	2.8%	-0.77 [-0.81, -0.73]		5.1.6 BT 2019 Chenhul D 0.19 0.03 39 0.32 0.09 39 4.0% -1.92 [-2.46, -1.30]
19 Yangxia L	-5.77			-3.65		47	2.7%	-2.12 [-2.40, -1.84]		2021 Culqing Z -2.9 0.02 60 -1.51 0.91 60 4.1% -2.151/2.60, -1.68
120 Wei H	-7.55			-4.54		40	2.8%	-3.01 [-3.13, -2.89]	-	2022 Methen L -0.5 0.45 129 -2.32 0.25 129 4.1% -3.2313.00,-2.80
20 Xinxin P	-1.88			-1.28		40	2.6%	-0.60 [-0.94, -0.26]		2023 Rubuan W -6.17 1.83 33 -4.38 2.89 33 4.0% -0.77 [1.27, -0.27] Subsould (95% CD 300 376 23.0% -3.20 [.4.12, -1.97]
120 Yalan H		2.33		-3.97		34				Heterogeneity: Tau" = 2.22; Chi" = 170.03; dt = 5 (P < 0.00001); i" = 97%; Test for overall effect Z = 5.11 (P < 0.00001)
							1.9%	-1.13 [-2.04, -0.22]		5.17W.HT
020 Yali Z	-5.51			-2.07		36 36	2.4%	-3.44 [-3.98, -2.90]		2010 Shijin Q -2.9 0.43 76 -2.39 0.42 74 4.1% -1.19[-1.54,-0.85] " 2021 Hisrogye C -2.81 0.62 72 -1.69 0.31 72 4.1% -2.27[-2.60,-1.65] "
21 Bing Y	-1.02			-0.86			2.8%	-0.16 [-0.23, -0.09]		Secondal (95% CI) 148 146 8.2% 1.73 [2.78, 0.67]  Hoterparenty Tay"= 0.54, Ch*= 14.99, df= 1 (# = 0.0001), #= 93%
021 Cuiqing Z	-2.15			-1.43		56	2.8%	-0.72 [-0.86, -0.58]		Test for overall effect Z = 3.20 (P = 0.001)
021 Hongye C		0.02		-1.51		60	2.7%	-1.39 [-1.62, -1.16]		5.1.8 WYT 2022 Yan C -5.11 1.2 48 -1.06 0.19 48 3.9% -4.88 (5.46,-3.89)
)21 Jiang H	-2.81			-1.69		72	2.7%	-1.12 [-1.28, -0.96]		Sectoral (95%C) 48 48 3.9% -4.68 [-5.46, -3.09]
121 Jinfeng S	-1.73			-0.87		54	2.8%	-0.86 [-0.89, -0.83]		Test for overall effect Z = 11.68 (P < 0.00001)
121 Ying L	-5.42			-4.14		40	2.3%	-1.28 [-1.85, -0.71]		5.1.9.GJ 2020 WeiH -1.00 0.01 47 -1.20 0.00 47 4.1% -0.701/-1.12,-0.290
122 An Z	-3.07			-1.69		49	2.5%	-1.38 [-1.80, -0.96]		Subinital (95% CI) 47 47 4.1% 4.70 [-1.12, 0.29]
22 Haitao X		1.42		-6.14		53	2.4%	-1.16 [-1.69, -0.63]		Test for overall effect Z = 3.31 (P = 0.0009)
22 Lei Z	-2.93			-1.72		60	2.4%	-1.21 [-1.74, -0.68]		5.1.101/Y1H 2018 Liven P -0.34 0.05 60 -0.05 0.95 60 4.1% -0.43[-0.79,-0.07]
22 Meizhen L	-2.96			-1.64		51	2.8%	-1.32 [-1.33, -1.31]		2010 Min Z - 1.56 0.7 36 -0.01 0.93 36 4.1% -0.01 [1.30, 0.42]
22 Ping W		0.45		-2.32		129	2.8%	-1.18 [-1.27, -1.09]	-	2022 Let Z 256 0.03 51 164 0.01 51 0.5% 58 59 [46 80, 50.38] Subbatu (95% Cb) 203 203 127% 5.56 (7.52, 2.61]
22 Yan C	-5.17			-3.72		60	2.8%	-1.45 [-1.50, -1.40]		Heteropenety Tau" = 5.01; Chi" = 213.00; df = 3.02; cf
122 Yu Z	-5.11			-1.06		48	2.6%	-4.05 [-4.39, -3.71]		5.5.11.40
23 Duanyang J	-1.76			-0.87		61	2.8%	-0.89 [-1.00, -0.78]	-	2015.Juling V -1.47 0.41 43 -0.04 0.50 43 4.1% -1.24[-1.71,-0.70]
23 Jiali Y	-2.84			-1.61		57	2.8%	-1.23 [-1.38, -1.08]	~	Subbolal (95% Cb) 122 122 8.1% -1.91[-3.20, -0.61]
23 Ruixuan W	-1.3	0.13	63	-0.67	0.07	63	2.8%	-0.63 [-0.67, -0.59]	•	Heterogeneity: Tau# = 0.02; Chi# = 17.05; df = 1 (P < 0.0001); I# = 94%; Test for overall effect Z = 2.80 (P = 0.004)
123 Xue F	-6.17	1.83	33	-4.38	2.69	33	1.6%	-1.79 [-2.90, -0.68]		5.1.12.11Y 2015.anging.H -1.3 0 50 -1 0 50 Notestmable
tal (95% CI)			2253			2240	100.0%	-1.31 [-1.53, -1.10]	•	2019 YangsisiL -7.55 0.38 40 -4.54 0.03 40 3.1% -11.06512.87,-9.25 4 Subtrat (05% C0) 50 50 10 3.1% -11.06512.87,-9.25 1 Histoprevity Not applicable
eterogeneity: Tau <sup>2</sup> =	0.43; Cł	hi² = 1	4540.78	3, df = 3	7 (P < )	0.00001	); I <sup>2</sup> = 10	0% -	-4 -2 0 2	Testfor oversill effect Z = 11.97 (P < 0.0001)
st for overall effect:	Z = 11.9	4 (P <	0.0000	1)					-4 -2 0 2 Favours (experimental) Favours (control)	4         Total (05): (1) Helesopere/t, Tay*e 2.42; Crk <sup>2</sup> 548:10.07; 2.267 + 0.00001); Pr 976; Test for ownail whet Z = 9.20 P < 0.00001); Pr 976; Test for ownail whet Z = 9.20 P < 0.00001); Pr 956 (96; Test for ownail whet Z = 9.20 P < 0.00001); Pr 956 (96; Favour (portmet/L); Favour (portm

BUN forest plot & BUN prescription forest plot.

	Experimen			ontrol			Mean Difference	Mean Difference	Experimental Control Std. Mean Difference Std. Mean Difference Study of Subgroup Mean SD Total Mean SD Total Weight N, Bandom, 95% CI N, Bandom, 95% CI
udy or Subgroup		Total			otal V		/, Random, 95% Cl	IV, Random, 95% Cl	6.1.1 GF 2014 Liping T -2.53 1.04 39 -1.51 0.62 39 5.7% -1.18 [-1.66,-0.70]
13 Yi S	-0.96 0.05		-0.34	0.11	52		-0.62 [-0.65, -0.59]	-	Subtotal (95% CI) 39 39 5.7% -1.18 [-1.66, -0.70]
14 Liping T	-2.53 1.04		-1.51	0.62			-1.02 [-1.40, -0.64]		Test for overall effect: Z = 4.79 (P < 0.00001)
14 Yalian H	-0.22 0.09		-0.1	0.01	37		-0.12 [-0.15, -0.09]		6.12.77
15 Bailong C	-0.5 0.1		-0.31	0.05	41		-0.19 [-0.22, -0.16]	-	2019 Ling W -2.34 0.85 56 -1.44 0.5 56 5.7% -1.28 [-1.69, -0.87]
15 Ming L	-0.089 0.009			0.007	53		-0.03 [-0.04, -0.03]	•	2020 Yali Z -0.45 0.12 36 -0.41 0.13 36 5.7% -0.32 [0.78, 0.15] Subtotal (95% Cl) 92 92 11.4% -0.81 [-1.75, 0.14]
15 Ting Z	-1.11 0.11	25	-0.53	0.07	25		-0.58 [-0.63, -0.53]	-	Heterogeneity: Tau# = 0.42; Chi# = 9.36; df = 1 (P = 0.002); I# = 89%
16 Lige L	-1.18 0.11	60	-0.72	0.05	60		-0.46 [-0.49, -0.43]	-	Test for overall effect: $Z = 1.67$ (P = 0.10)
16 Shulan W	-0.73 0.12		-0.42	0.09			-0.31 [-0.35, -0.27]	-	6.1.3 SD 2023 Jiaii Y -0.89 0.09 63 -0.65 0.06 63 5.7% -3.12 [-3.84,-2.59]
16 Tao L	-1.24 0.24		-0.93	0.06			-0.31 [-0.40, -0.22]		2023 Julii 10.89 0.09 63 -0.65 0.06 63 5.7% -3.12[-3.64, -2.59] Subtotal (95% Cl) 63 63 5.7% -3.12[-3.64, -2.59]
16 Xiaojing D	-1.03 0.27		-0.48	0.03	49		-0.55 [-0.63, -0.47]	-	Histerogeneity: Not applicable Test for overall effect: Z = 11.86 @ < 0.00001)
17 Ni Z	-0.81 0.04		-0.27	0.13	53		-0.54 [-0.58, -0.50]	-	6.1.4 YH
17 Ping D	-0.072 0.065		-0.042			2.9%	-0.03 [-0.07, 0.01]	1	6.1.4 YH 2017 Xisoli Z -0.23 0.003 53 -0.21 0.004 53 5.5% -5.82 [-6.48, -4.76]
17 Rucui Y	-0.32 0.001	42	-0.2	0.02	38		-0.12 [-0.13, -0.11]		2018 Aimin Hu -0.21 0.01 50 -0.18 0.003 50 5.6% -4.03 [-4.72, -3.34] ★ Subtotal (95% CI) 103 103 11.1% -4.80 [-6.35, -3.25] ★
17 Xiaoli Z	-0.23 0.003		-0.21	0.004	53	3.0%	-0.02 [-0.02, -0.02]	1	Heterogeneity: Tau* = 1.10; Chi* = 7.91, df = 1 (P = 0.005); I* = 87%
18 Aimin Hu	-0.21 0.01	50		0.003	50		-0.03 [-0.03, -0.03]		Test for overall effect: $Z = 6.07 (P < 0.00001)$
18 Liwen P	-0.52 0.5		-0.45	0.11	60	2.5%	-0.07 [-0.20, 0.06]	-+	6.1.5 BT
18 Xingguo L	-0.034 0.009			0.002	64		-0.01 [-0.01, -0.01]	1	2014 Yalian H -0.22 0.09 31 -0.1 0.01 37 5.7% -1.94 [-2.52,-1.36]
19 Fangqiang C	-0.73 0.43	40	-0.22	0.04	39	2.5%	-0.51 [-0.64, -0.38]		2021 Husizhi L -1.09 0.08 47 -0.46 0.05 46 5.1% -9.34 [-10.77, -7.91]
19 Gangyi C	-0.62 0.05	79	-0.34	0.04	79	3.0%	-0.28 [-0.29, -0.27]	-	2022 Yu Z -0.59 0.23 65 -0.32 0.22 61 5.7% -1.19 [-1.57, -0.01] Subtotal (95% Cl) 203 204 22.1% -4.12 [-6.45, -1.78]
19 Ling W	-2.34 0.85	56	-1.44	0.5	56	1.7%	-0.90 [-1.16, -0.64]		Heterogeneity: Tau <sup>4</sup> = 5.49; Chi <sup>4</sup> = 164.83; df= 3 (P < 0.00001); i <sup>4</sup> = 98% Test for overall effect: Z = 3.45 (P = 0.0006)
9 Rong Y	-0.62 0.16	33	-0.27	0.01	33	2.9%	-0.35 [-0.40, -0.30]	-	2419-0229-0229-0229-0229-02-02-0229-02-02-0229-02-02-02-02-02-02-02-02-02-02-02-02-02-
9 Sugin W	-0.53 0.01	66	-0.13	0.002		3.0%	-0.40 [-0.40, -0.40]		6.1.6 WJHT 2015 Ting Z -1.11 0.11 25 -0.53 0.07 25 5.1% -6.19 [-7.57,-4.81]
19 Xiaoze S	-0.61 0.18	47	-0.42	0.09	47	2.9%	-0.19 [-0.25, -0.13]	-	Subtotal (95% CI) 25 25 5.1% -6.19 [-7.57, -4.81]
19 Yangxia L	-0.18 0.04	40	-0.07	0.04	40	3.0%	-0.11 [-0.13, -0.09]	-	Heterogeneity. Not applicable Test for overall effect: Z = 8.79 (P < 0.00001)
20 Xinxin P	-0.73 0.44	36	-0.33	0.3	34	2.2%	-0.40 [-0.58, -0.22]		6.1.7 WI
20 Yali Z	-0.45 0.12	36	-0.41	0.13	36	2.9%	-0.04 [-0.10, 0.02]	~	2017 Rucui Y -0.32 0.001 42 -0.2 0.02 38 5.1% -8.62 [-10.05, -7.18]
21 Cuiqing Z	-0.13 0.01	60	-0.06	0.02	60	3.0%	-0.07 [-0.08, -0.06]	•	2022 Yan C -0.07 0.024 48 -0.054 0.017 48 5.7% -0.76 [-1.18, -0.35] = Subtotal (95% Cb 90 86 10.8% -4.66 [-12.35, 3.04]
21 Huaizhi L	-1.09 0.08	47	-0.46	0.05	46	2.9%	-0.63 [-0.66, -0.60]	~	Heterogeneity, Tau# = 30.54; Chi# = 105.78; df = 1 (P < 0.00001); i# = 99% Test for overall effect. Z = 1.19 (P = 0.24)
21 Jinfeng S	-0.97 0.17	40	-0.48	0.05	40	2.9%	-0.49 [-0.54, -0.44]	-	
22 Haitao X	-0.88 0.19		-0.29	0.33	60		-0.59 [-0.69, -0.49]	-	6.1.8 GJ 2017 NIZ -0.81 0.04 53 -0.27 0.13 53 5.5% -5.57 [-6.43,-4.72]
22 Lei Z	-0.12 0.01	51	-0.06	0.02	51	3.0%	-0.06 [-0.07, -0.05]		Subtotal (95% Cl) 53 53 5.5% -5.57 [-6.43, -4.72]
22 LI T	-2.15 0.39	43	-1.45	0.02	41	2.6%	-0.70 [-0.82, -0.58]	-	Heterogeneity: Not applicable Testfor overall effect. Z = 12.79 (P < 0.00001)
22 Yan C	-0.07 0.024	48	-0.054	0.017	48	3.0%	-0.02 [-0.02, -0.01]	1	6.19.JB
22 Yu Z	-0.59 0.23	65	-0.32	0.22	61	2.8%	-0.27 [-0.35, -0.19]		2019 Gangel C -0.62 0.05 79 -0.34 0.04 79 5.6% -6.151-6.91,-5.40
23 Jiali Y	-0.89 0.09	63	-0.65	0.06	63	2.9%	-0.24 [-0.27, -0.21]	-	Subtotal (95% CI) 79 79 5.6% -6.15 [-6.91, -5.40]
23 Xue F	-0.93 0.05	48	-0.58	0.05	53	3.0%	-0.35 [-0.37, -0.33]		Test for overall effect: $Z = 15.98 \text{ (P} < 0.00001)$
al (95% CI)		1760		1	755 1	00.0%	-0.30 [-0.35, -0.25]	•	6.1.10 EV11N 2018 Liwen P -0.52 0.5 60 -0.45 0.11 60 5.7% -0.19 [-0.55, 0.17]
terogeneity: Tau <sup>2</sup> =	0.02; Chi <sup>2</sup> = 85	778.70,	df = 35 (F	o < 0.000	01); l <sup>2</sup> =	100%		-1 -0.5 0 0.5 1	2022 Lei Z -0.12 0.01 51 -0.06 0.02 51 5.6% -3.77 [-4.42,-3.11] Subtotal (95% CI) 111 111 11.3% -1.97 [-5.47, 1.53]
t for overall effect.	Z=11.30 (P <	0.00001						Favours (experimental) Favours (control)	Heterogeneith: Tau <sup>a</sup> = 6.31; Chi <sup>a</sup> = 88.09, df = 1 (P < 0.00001); l <sup>a</sup> = 99% Test for overall effect: Z = 1.10 (P = 0.27)
								r avours (experimental) - r avours (control)	
									6.1.11 MY 2019 Yangxia L -0.18 0.04 40 -0.07 0.04 40 5.6% -2.721-3.34 -2.11
									Subtotal (95% Cl) 40 40 5.6% -2.72 [-3.34, -2.11]
									Heterogeneity: Notapplicable Test for overall effect: Z = 8.67 (P < 0.00001)
									Total (95% CD 898 895 100.0% -3.60 [-4.54, -2.66]
									Heterogeneity, Tau* = 4.00, Chi* = 924.63, df = 17 (P < 0.00001), I* = 98% Test for overall effect Z = 7.49 (P < 0.00001)
									Test for subarous differences: Chi# = 205.08. df = 10 (P < 0.00001). P = 95.1% Favours [experimental] Favours [control]
GURE 8	act plat (	2/1	+	Dree	orin	tion f	oract plat		
1h-utp fore	est plot a	r 24r	i-utp	pres	crip	uon t	orest plot.		

compared to the control group was observed in the BT group (SMD = -3.24, 95% CI [-4.99, -1.49],  $I^2 = 98\%$ , p < 0.00001), while the least significant reduction was observed in the YZ group (SMD = -0.08, 95% CI [-0.52, 0.36], p = 0.72) (Figure 9).

33 studies were included in the analysis of the HbA1c outcome measure. The results showed that traditional Chinese medicine decoctions as an adjunctive treatment were superior to the control group in reducing HbA1c levels in patients with diabetic nephropathy (MD = -0.68, 95% CI [-0.87, -0.49],  $I^2 = 100\%$ , p < 0.00001). Subgroup analysis based on the composition of the traditional Chinese medicine decoctions showed that there was no statistically significant difference in the reduction of HbA1c levels between the GF group, YZ group, and HY group compared to the control group (p = 0.25, p = 0.80, p = 0.29). The most significant reduction in HbA1c levels compared to the control group was observed in the JB group (SMD = -13.21, 95% CI [-15.17, -11.25], p < 0.00001), while the least significant reduction was observed in the YZ group (SMD = -0.27, 95% CI [-0.74, 0.19], p = 0.80) (Figure 10).

## 3.6 Publication bias and sensitivity analysis

The funnel plots showed asymmetry for SCR and UAER (Figure 11C; Figure 11D), indicating potential publication bias. The symmetry of the other plots was acceptable. Egger's test was conducted to assess the publication bias. The results revealed significant publication bias for clinical efficacy and SCR (p <


0.00001, p = 0.012) (Figure 12A; Figure 12C), while no publication bias was observed for the remaining results (p = 0.642, p = 0.831, p = 0.742, p = 0.165, p = 0.092, p = 0.061) (Figures 12B, D, E, F, G, H). Sensitivity analysis using the one-by-one exclusion method did not reveal any significant sources of sensitivity.


# 4 Discussion

China has become the country with the highest number of diabetes patients in the world, and it is estimated that by 2045, there will be 170 million diabetes patients in China (International Diabetes Federation, 2023). Diabetic nephropathy, as a common complication of diabetes, is also one of the leading causes of death among diabetes patients, imposing a heavy social and economic burden on China and the world. Given this burden, timely diagnosis, treatment, and management of diabetic nephropathy in its early stages are of significant importance to improve symptoms, enhance quality of life, and improve prognosis for diabetic nephropathy patients. Traditional Chinese medicine has been widely used in the treatment of diabetic nephropathy in China for a long time. Diabetic nephropathy falls within the TCM categories of "xiao ke" (wasting and thirst disorder), "shui zhong" (odema), "xu lao" (asthenia), "guan ge" (urinary block and vomiting). Zhang Jingyue mentioned in the Classified Canon that if the wasting and thirst disorder is severe and uncontrolled, it will affect the liver and kidneys (Jiangyi et al., 2022).

have Cubara		imentai			ontrol	Tetal	Mainh	Mean Difference	Mean Difference	Study or Subgroup	Experim Mean S			Control n SD			td. Mean Difference IV, Random, 95% CI		Std. Mean Differen	
ly or Subgroup	Mean	SD T						IV, Random, 95% Cl	IV, Random, 95% Cl	- 7.1.1 GF										
3 Yi S	-0.42				0.08	52	2.9%	0.01 [-0.09, 0.11]	1	2014 Angui J	-0.31 0.0			3 0.2		5.4%	-0.07 [-0.57, 0.44]		_1	
4 Angui J	-0.31		30	-0.3		30	2.9%	-0.01 [-0.09, 0.07]	1	2014 Liping T Subtotal (95% CI)	-5.08 0.8	89 3 6	9 -3.3	1 1.98		5.4%	-1.14 [-1.62, -0.66] -0.61 [-1.66, 0.45]			
4 Liping T	-5.08				1.98	39	1.8%	-1.77 [-2.45, -1.09]		Heterogeneity: Tau <sup>2</sup> = I	.52 Chi#=			= 0.003			-0.01[-1.00, 0.45]		1	
5 Bailong C	-7.52			-7.59		41	1.0%	0.07 [-1.12, 1.26]		Test for overall effect 2	= 1.13 (P	= 0.26)								
5 Beide S	-1.12			-0.33		89	2.9%	-0.79 [-0.84, -0.74]	-											
5 Jialing Y	-5.68	1.46	43	-2.94	0.99	43	2.1%	-2.74 [-3.27, -2.21]		7.1.2 YZ										
Jianmin Y	-0.32	0.05	48	-0.05	0.08	47	2.9%	-0.27 [-0.30, -0.24]		2020 Yali Z Subtotal (95% CB	-1.25 0	1.9 4	0 -1.1	8 0.82		5.5%	-0.08 [-0.52, 0.36] -0.08 [-0.52, 0.36]		1	
Jingjing H	-2.1	0.12	50	-1.2	0.07	50	2.9%	-0.90 [-0.94, -0.86]		Heterogeneity: Not app	licable		•		40	3.3 %	-0.00[-0.52, 0.50]		1	
Ming L	-0.37	0.23	52	-0.18	0.21	53	2.9%	-0.19 [-0.27, -0.11]	~	Test for overall effect 2		= 0.72)								
Lige L	-3.17	36	60	-2.58	0.04	60	2.9%	-0.59 [-0.68, -0.50]	-											
Shulan W	-3.49			-2.91		65	2.8%	-0.58 [-0.78, -0.38]		7.1.3 YH	10102011010				1.000	0.000				
Tao L	-0.2				0.15	32	2.9%	-0.06 [-0.19, 0.07]	-	2017 Xiaoli Z 2018 Aimin Hu	-0.29 0.2		3 -0.2			5.5%	-0.46 [-0.85, -0.08] -1.69 [-2.15, -1.23]			
	-0.76				0.52	49	2.6%			Subtotal (95% CI)	-3.15 1.0	10		5 0.58	103		-1.07 [-2.27, 0.13]		•	
Xiaojing D						35		0.41 [0.12, 0.70]		Heterogeneity: Tau* = I	.70: Chi#=			< 0.00			- nor (-mart or of			
Ping D		0.6		-0.66			2.8%	-0.13 [-0.35, 0.09]		Test for overall effect 2	= 1.74 (P	= 0.08)								
Rucui Y	-3.26				0.78	38	2.4%	-0.74 [-1.16, -0.32]												
Xiaoli Z	-0.29				0.08	53	2.9%	-0.08 [-0.15, -0.01]	1	7.1.4 BT										
Aimin Hu	-3.15				0.58	50	2.6%	-1.40 [-1.72, -1.08]		2019 Chenhui D 2021 Cuiging Z	-2.21 0.8		9 -2.1			5.5%	-0.13 [-0.57, 0.32] 14.12 [-15.97, -12.27]	_	1	
liwen P	-0.42	0.01	60	0.01	0.01	60	2.9%	-0.43 [-0.43, -0.43]	· · ·	2021 Cuiqing Z 2021 Huaizhi L	-4.26 0.7		7 -2.5			3.6% -	-2.02 [-2.52, -1.52]		+	
Min Z	-2.46	0.66	36	-1.58	0.36	36	2.7%	-0.88 [-1.13, -0.63]		2021 Jiang H	-3.41 0.8		4 -2.7		54	5.5%	-0.82 [-1.21, -0.42]		-	
Shijian Q	-1.24	0.42	76	-0.8	0.23	74	2.9%	-0.44 [-0.55, -0.33]	~	2023 Xin Y	-3.28 1.2	23 3	9 -2.1		39	5.4%	-1.07 [-1.55, -0.59]		-	
Gaoyi Z	-1.85	3.88	40	-1.43	0.23	40	2.7%	-0.42 [-0.70, -0.14]		Subtotal (95% CI)		23		-	238		-3.24 [-4.99, -1.49]		•	
Gingguo L		1.5			0.98	64	2.3%	-0.17 [-0.61, 0.27]		Heterogeneity: Tau <sup>2</sup> = 3				(P < 0.0	0001); I*=	98%				
Chenhui D	-2.21				0.54	39	2.6%	-0.09 [-0.41, 0.23]	-	Test for overall effect 2	= 3.63 (P	= 0.000	3)							
Rong Y	-4.2			-3.81		33	1.9%	-0.39 [-1.02, 0.24]		7.1.5 WJTH										
	-2.21				1.58	62	1.8%			2018 Shijian Q	-1.24 0.4	42 7	6 -0.	8 0.23	74	5.5%	-1.29 [-1.64, -0.94]			
Sugin W								-0.55 [-1.26, 0.16]		Subtotal (95% CI)		7	6		74	5.5%	-1.29 [-1.64, -0.94]		•	
Gaoze S	-6.05				0.39	47	2.4%	-1.52 [-1.92, -1.12]		Heterogeneity: Not app										
Yangxia L	-1.51				0.05	44	2.9%	-1.26 [-1.31, -1.21]	•	Test for overall effect: 2	= 7.16 (P	< 0.000	01)							
Zhixiong T		0.9			0.82	40	2.5%	-0.07 [-0.45, 0.31]		7.1.6 YYT										
Xinxin P	-0.85	0.45	33	+0.17	0.14	32	2.8%	-0.68 [-0.84, -0.52]		2017 Rucui Y	-3.26 1.1	14 4	2 -25	2 0.78	38	5.4%	-0.74 (-1.20, -0.29)		-	
Yalan H	-5.98	1.43	36	-6.03	1.8	34	1.7%	0.05 [-0.71, 0.81]		2022 Yan C	-1 0.4		8 -0.5	5 0.36		5.5%	-1.07 [-1.50, -0.64]			
Yali Z	-1.77	0.91	36	-0.75	0.31	36	2.6%	-1.02 [-1.33, -0.71]		Subtotal (95% CI)		9				10.9%	-0.91 [-1.23, -0.60]		•	
Bing Y	-3.53	1.2	36	-3.93	1.53	36	1.9%	0.40 [-0.24, 1.04]		Heterogeneity: Tau <sup>a</sup> = I				= 0.31);	P= 3%					
Cuiging Z	-3.86				1.11	56	2.4%	-1.13 [-1.52, -0.74]		Test for overall effect 2	= 5.67 (P	< 0.000	01)							
Huaizhi L	-2.8				0.19	60	2.9%	-1.92 [-1.97, -1.87]	-	7.1.7 JB										
Jiang H	-4.26				0.86	46	2.6%	-1.67 [-2.00, -1.34]		2015 Jialing Y	-5.68 1.4	46 4	3 -2.9	4 0.99	43	5.4%	-2.18 [-2.72, -1.64]		+	
						54				Subtotal (95% CI)		4	3		43	5.4%	-2.18 [-2.72, -1.64]		•	
An Z	-3.41				0.63		2.6%	-0.63 [-0.92, -0.34]		Heterogeneity: Not app										
Lei Z	-4.27			-2.85		53	2.9%	-1.42 [-1.51, -1.33]	~	Test for overall effect 2	= 7.93 (P	< 0.000	01)							
LIT	-2.9	0			0.16	51		Not estimable		7.1.8 BYTH										
Yan C	-2.84	0.87	43	·2.62	0.68	41	2.6%	-0.22 [-0.55, 0.11]		2018 Liwen P	-0.52 0	15 6	0 -0.4	5 0.11	60	5.5%	-0.19 [-0.55, 0.17]		-	
Xin Y	-1	0.47	48	-0.55	0.36	48	2.8%	-0.45 [-0.62, -0.28]		2018 Min Z	-2.46 0.8			8 0.36		5.4%	-1.64 [-2.18, -1.10]		+	
										2021 Bing Y	-3.53 1		6 -3.9			5.4%	0.29 [-0.18, 0.75]		+	
(95% CI)		1	927			1912	100.0%	-0.64 [-0.79, -0.49]		2022 Lei Z	-2.9 0.1		1 -1.0	4 0.16			-11.54 [-13.20, -9.88]	_	-	
rogeneity: Tau <sup>2</sup> =	0.19; Chi	<sup>2</sup> = 660	8.24	df = 38	B (P < 0	000011	: I <sup>2</sup> = 999	6		Subtotal (95% CI) Heterogeneity: Tau <sup>a</sup> = 4	01-05-	18		/D = 0 ~	183		-3.02 [-5.23, -0.80]		-	
for overall effect:									-2 -1 0 1 2	Test for overall effect 2				(r = 0.0	0001), (*=	070				
									Favours (experimental) Favours (control)	. Juston orderen dilbert 2	a.v. (* .	0.000								
										7.1.9 HY										
										2019 Yangxia L	-4.2 1.2			1 1.37		5.4%	-0.30 [-0.78, 0.19]		1	
										Subtotal (95% CI) Heterogeneity: Not app	liceble	3	3		33	5.4%	-0.30 [-0.78, 0.19]		1	
										Heterogeneity: Not app Test for overall effect 2		= 0.225								
										Vestion overall effect 7	= 1.20 (P)	= 0.23)								
										Total (95% CI)		87			869 1		-1.74 [-2.32, -1.16]		•	
										Heterogeneity: Tau* = 1	.55; Chi?=	= 506.45	5, df = 18	B (P < 0.)				20 -10		10
										Test for overall effect 2									erimental] Favour	
										Test for subarous diffe	rences: Ch	nr= 55.1	98. df = 1	8 (P < 0.	.00001). P	*= 85.7%				
JRE 9																				
G forest p	1						e	e vel e é												

udy or Subaroup	Mean SD	Total	Mean	SD	Total V	Weight	IV. Random, 95% CI	IV. Random, 95% CI	Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% Cl IV, Random, 95% Cl
13 Yi S	-0.06 0.36	52		0.01	52	3.2%	0.04 [-0.06, 0.14]	+	- 8.1.2 YZ 2020 Yall Z -1.75 1.03 36 -1.5 0.75 36 7.9% -0.27 F0.74 0.19
15 Bailong C	-2.43 0.59		-2.18		41	3.1%	-0.25 [-0.44, -0.06]		Subtotal (95% Cl) 36 36 7.9% -0.27 [-0.74, 0.19]
15 Beide S	-1 0.09		-0.11		89	3.2%	-0.89 [-0.96, -0.82]	-	Heterogeneity: Not applicable
15 Jialing Y	-5.29 2.75		-2.95		43	1.5%	-2.34 [-3.46, -1.22]		Test for overall effect. Z = 1.16 (P = 0.25)
15 Jianmin Y	-0.45 0.03	48	0.02		47	3.2%	-0.47 [-0.48, -0.46]		8.1.3 YH
15 Jingjing H	-1.5 0.14	50		0.11	50	3.2%	-0.50 [-0.55, -0.45]		2017 Xiaoli Z -1.68 0.14 53 -1.09 0.02 53 7.6% -5.86 [-6.75, -4.97]
15 Mina L	-1.61 0.39		-1.11		53	3.2%	-0.50 [-0.63, -0.37]	-	2018 Almin Hu -0.01 0.17 50 -0.47 0.07 50 7.8% 3.51 [2.88, 4.14]
16 Lige L	-4.1 0.11		-3.85		60	3.2%	-0.25 [-0.28, -0.22]		Subtotal (95% Cl) 103 103 15.3% -1.17 [-10.35, 8.01] Heterogeneity: Tau <sup>a</sup> = 43.73; Chi <sup>a</sup> = 283.14, df = 1 (P < 0.00001); i <sup>a</sup> = 100%
16 Tao L	-0.14 0.09		-0.04		32	3.2%	-0.10 [-0.14, -0.06]	-	Testforwerall effect 2 0.25 (P 0.80)
16 Xiaojing D	-1.32 0.32		-0.85		49	3.2%	-0.47 [-0.56, -0.38]	-	
17 Ping D	-0.56 0.09		-0.31		35	3.2%	-0.25 [-0.36, -0.14]	+	8.1.4 JH 2023 Duarwang J -4.15 1.12 57 -3.19 0.98 57 7.9% -0.91 F1.29 -0.52
17 Rucui Y	-1.78 0.55		-0.31		35	3.1%	-1.55 [-1.73, -1.37]	-	2023 Duarrang 0 -4.15 1.12 57 -5.19 0.96 57 7.9% -0.91 [1.29, 0.52]
17 Xiaoli Z	-1.68 0.14		-0.23		53	3.1%	-0.59 [-0.63, -0.55]		Heterogeneity: Not applicable
					50				Test for overall effect: Z = 4.60 (P < 0.00001)
18 Aimin Hu	-1.01 0.17		-0.47		50	3.2%	-0.54 [-0.59, -0.49]	+	8.15 BT
18 Shijian Q	-1.42 0.32 -1.11 0.03	76 65	-0.54	0.4	64	3.2%	-0.88 [-1.00, -0.76] -0.01 [-0.02, 0.00]		2019 Chenhui D -2.6 0.29 39 -2.25 0.14 39 7.8% -1.52 [-2.03,-1.01]
18 Xingguo L 19 Chenhui D	-1.11 0.03		-1.1		64 39	3.2%		+	2021 Jiang H -2.5 0.33 54 -1.79 0.28 54 7.8% -2.30 [-2.79, -1.81] +
							-0.35 [-0.45, -0.25]		2023 Xin Y -4.05 0.07 39 -2.14 0 39 Notestimable Subtotal (95% CI) 132 132 15.7% -1.92 [-2.68, -1.15] ◆
19 Rong Y 19 Suain W	-2.57 1.07 -1.83 2	33 66	-1.81		33 62	2.7%	-0.76 [-1.21, -0.31]		Heterogeneity, Tau <sup>2</sup> = 0.24; Chi <sup>2</sup> = 4.72, df = 1 (P = 0.03); l <sup>2</sup> = 79%
	-1.83 2	40	-1.3		40	2.0%	-0.53 [-1.08, 0.02]		Test for overall effect: $Z = 4.90$ (P < 0.00001)
19 Yangxi F							-0.13 [-0.63, 0.37]		8.1.6 WJHT
19 Yangxia L	-1.32 0.19 -0.68 0.2		-0.15		44	3.2%	-1.17 [-1.23, -1.11]		2018 Shiilian Q +1.42 0.32 76 +0.54 0.4 74 7.9% +2.42 F2.84 +2.001
19 Zhixiong T							-0.59 [-0.80, -0.38]		Subtotal (95% CI) 76 74 7.9% -2.42 [-2.84, -2.00]
20 Xinxin P	-2.51 1.41		-1.93		34	2.5%	-0.58 [-1.18, 0.02]		Heterogeneity: Not applicable Test for overall effect: Z = 11.20 (P < 0.00001)
20 Yalan H	-1.33 1.06		-0.63		36	2.9%	-0.70 [-1.06, -0.34]		lestion overall effect: 2 = 11.20 (P < 0.00001)
20 Yali Z	-1.75 1.03	36	-1.5		36	2.8%	-0.25 [-0.67, 0.17]		8.1.7 YYT
21 Bing Y	-1.76 1.02		-0.92		56	3.0%	-0.84 [-1.16, -0.52]	-	2017 Rucul Y -1.78 0.55 42 -0.23 0.18 38 7.7% -3.68[4.41,-2.95]
21 Jiang H	-2.5 0.33		-1.79		54	3.2%	-0.71 [-0.83, -0.59]		2022 Yan C -1.43 0.17 48 -0.71 0.6 48 7.9% -1.62 [-2.08,-1.16] Subtotal (95% CI) 90 86 15.6% -2.63 [-4.64, -0.61]
22 An Z	-4.85 0.39		-2.77		53	3.2%	-2.08 [-2.19, -1.97]		Heterogeneity: Tau# = 2.02; Chi# = 21.70, df = 1 (P < 0.00001); I# = 95%
22 Haitao X	-0.5 0.06		-0.01		60	3.2%	-0.49 [-0.54, -0.44]	_	Test for overall effect: Z = 2.56 (P = 0.01)
22 LI T	-1.18 0.55		-0.32		41	3.1%	-0.86 [-1.03, -0.69]		8.1.8 JB
22 Yan C	-1.43 0.17		-0.71	0.6	48	3.1%	-0.72 [-0.90, -0.54]		2015 Jianmin Y -0.45 0.03 48 0.02 0.04 47 6.3% -13.21 [-15.17,-11.25] *
23 Duanyang J	-4.15 1.12		-3.19		57	2.9%	-0.96 [-1.35, -0.57]		Subtotal (95% CI) 48 47 6.3% -13.21 [-15.17, -11.25] *
23 Xin Y	-4.05 0.07	39	-2.14	0.07	39	3.2%	-1.91 [-1.94, -1.88]		Heterogeneity: Not applicable Test for overall effect. Z = 13.21 (P < 0.00001)
tal (95% CI)		1608			4504	100.01/	-0.68 [-0.87, -0.49]	▲	reactor oreran energy 2 = 13.21 (* < 0.00001)
terogeneity: Tau <sup>2</sup> =	0.00.01.7.40							· · · · · · · · · · · · · · · · · · ·	8.1.9 BYTH
				2 (P < U	.00001	); P=10	0%	-2 -1 0 1 2	2021 Bing Y -1.76 1.02 56 -0.92 0.68 56 7.9% -0.96 [-1.35, -0.57] Subtotal (95% CI) 56 56 7.9% -0.96 [-1.35, -0.57] ♦
st for overall effect:	Z = 0.91 (P < 0	.00001	· · · ·					Favours [experimental] Favours [control]	Heterogeneity. Not applicable
									Test for overall effect: Z = 4.81 (P ≺ 0.00001)
									8.1.10 HY
									2015 Jingling H -1.5 0.14 50 -1 0.11 50 7.7% -3.94[-4.62,-3.26]
									2019 Yangxia L -2.23 1.11 40 -2.1 1.15 40 7.9% -0.11 [-0.55, 0.32]
									Subtotal (95% CI) 90 90 15.6% -2.02 [-5.77, 1.73] Heterogeneity: Tau <sup>a</sup> = 7.24; Chi <sup>a</sup> = 85.69, df = 1 (P < 0.00001); P = 99%
									Heterogenemy, raume / .24, Chine esc.es, or = 1 (P < 0.00001); P = 99% Testfor overall effect / 2 = 1.05 (P = 0.29)
									Total (95% CI) 688 681 100.0% -2.39 [-3.47, -1.31] Heterogeneity: Tau <sup>a</sup> = 3.79; Chi <sup>a</sup> = 661.25, df = 12 (P < 0.00001); P = 98%
									Heterogenery, rau* = 3, 9; Cn* = obi. 25, dt = 12 (* < 0.00001); r* = 98%
									Test for subaroup differences: Chi# = 198.34. df = 8 (P < 0.00001). I# = 96.0% Favours (experimental) Favours (control)





Review by Wang B (Wang et al., 2011) reported that Chinese medicines could relieve several symptoms of diabetic nephropathy, improve the quality of life, reduce proteinuria levels and kidney damage, and further improve renal function via multiple pathways. There are many meta-analysis studies of other TCM dosage forms for treating diabetic nephropathy. For example, Long C's network meta-analysis (Long et al., 2023) reported that the total effective rate of combined Salvia miltiorrhiza injection, Danshen-Chuanxiongqin injection, Danhong injection, Huangqi injection, and Shenkang injection combined with alprostadil injection (PGE1) was better than PGE1 alone. Within all subgroups, they found that PGE1+Shenkang injection was most effective for glomerular filtration function, while PGE1+Danhong injection was most effective for urinary protein-related indices. Shi RY's study (Shi et al., 2023) showed that combining western medicine and Chinese patent medicine was superior to western medicine alone in reducing serum creatinine (Scr), blood urea nitrogen (BUN), and urinary albumin excretion rate (UAER), and improving the total effective rate of treatment. The focus of our study on TCM decoctions is due to the fact that TCM decoctions are a widely used clinical dosage

form in China, and it has been found that the supramolecular structure in a TCM decoction can not only serve as a drug carrier to promote the absorption and distribution of medicinal components but may also exhibit biological activities superior to those of single active ingredients or their physical mixtures (Gao et al., 2022).

This study found that the adjunctive use of traditional Chinese medicine decoctions significantly improved clinical efficacy and reduced levels of SCR, BUN, UAER, 24 h-utp, FPG, and HbA1c in the treatment of diabetic nephropathy. The safety profile of traditional Chinese medicine decoctions was not statistically different from the control group. Sensitivity analysis did not reveal any significant sources of sensitivity. However, there was serious publication bias in terms of clinical efficacy and SCR results, while no significant publication bias was observed in the remaining results.

In this study, it was found that the Chinese medicines used as adjunctive treatment for diabetic nephropathy were mostly tonic, blood-activating, astringent, dampness-resolving, interior heatclearing, and purgative medicines.

The top five Chinese medicine in terms of frequency were *Astragalus mongholicus Bunge* [Fabaceae; Astragali mongholici radix](58 times), *Salvia miltiorrhiza Bunge* [Lamiaceae; Radix et rhizoma salviae miltiorrhizae] (42 times), *Dioscorea oppositifolia L.* [Dioscoreaceae; Dioscoreae rhizoma] (38 times), *Poria cocos (Schw.) Wolf* [Polyporaceae; Poria] (38 times), and *Cornus officinalis Siebold* & Zucc. [Cornaceae; Corni fructus] (35 times).

Astragalus mongholicus Bunge [Fabaceae; Astragali mongholici radix] functions as a tonic for the spleen qi and as diuretic for resolving edema. Its main active metabolites include Astragalus polysaccharides, astragaloside IV and Astragalus flavone. Studies have shown that Astragalus polysaccharides can reduce the expression of inflammatory cytokines and inhibit the TLR4/NF-KB pathway, thereby alleviating renal inflammation and reducing kidney damage (Guo M. et al., 2023; Guo C. et al., 2023). Astragaloside IV is selected as a chemical marker in the Chinese Pharmacopoeia for quality control purposes. It has been proven to improve diabetic kidney disease by counteracting oxidative stress, alleviating endoplasmic reticulum stress, regulating calcium homeostasis, reducing inflammation, improving vascular function, and improving the transition from epithelial to mesenchymal cells (Gao et al., 2023). Astragalus flavone reduce oxidative damage induced by high glucose levels by protecting intracellular antioxidant enzyme activity and enhancing endogenous antioxidant function (Tang et al., 2018).

According to *Ben Cao Zheng Yi*, *Salvia miltiorrhiza Bunge* [Lamiaceae; Salviae Miltiorrhizae Radix et Rhizoma] can internally reach the organs, transform stasis, and relieve obstructions, while externally, it benefits the joints and promotes circulation in the meridians. It possesses the abilities to transform stasis, clear heat, relieve abscesses, and calm restlessness. The active metabolites in *Salvia miltiorrhiza Bunge* [Lamiaceae; Radix et rhizoma salviae miltiorrhizae] mainly consist of tanshinones and phenolic acids. Tanshinones can delay the progression of diabetic kidney disease by inhibiting Txnip/NLRP3 inflammasomes (Wu et al., 2023), while phenolic acids can inhibit AGE-RAGE and restore glomerular endothelial function, alleviating renal structural deterioration and effectively improving early-stage diabetic nephropathy (Hou et al., 2017). *Dioscorea oppositifolia L.* [Dioscoreaceae; Dioscoreae rhizoma] also known as Chinese yam, serves both as a food and a medicinal botanical drug. It can tonify qi, nourish yin, and strengthen the lungs, spleen and kidneys. It is rich in various bioactive metabolites and has effects such as antioxidant, antiaging, and immune regulation. The Diosgenin from Dioscorea oppositifolia L improves diabetic nephropathy by enhancing autophagy and mitochondrial autophagy, as well as improving mitochondrial dynamics in a CaMKK2-dependent manner (Zhong et al., 2023).

*Poria cocos (Schw.) Wolf* [Polyporaceae; Poria] possesses diuretic and dampness-draining properties, calming the heart and relieving restlessness. It is mainly used to treat odema and phlegm-fluid disorders. The main metabolites of *Poria cocos (Schw.) Wolf* [Polyporaceae; Poria] are Wolfiporia cocos polysaccharide can inhibit the over-expression of the Bax gene in the renal tissues of diabetic mice, thus inhibiting the trend of cellular apoptosis in diabetic kidney disease and demonstrating a certain preventive effect (Huang et al., 2016).

*Cornus officinalis Siebold & Zucc.* [Cornaceae; Corni fructus] has a sour and sweet taste, a slightly warm property, and belongs to the liver and kidney meridians. It functions as a tonic for kidney qi, nurishing kidney yin, semen-secure and urine-astringing. Extracts of *Cornus officinalis Siebold & Zucc.* [Cornaceae; Corni fructus] can inhibit the expression of FN and IL-50 in mesangial cells stimulated by high glucose, thereby improving diabetic nephropathy (Ma et al., 2014).

This study included 66 clinical randomized controlled trials of Chinese medicine decoctions as adjunctive treatment for diabetic nephropathy and conducted a comprehensive analysis. It is currently the largest meta-analysis in this field, confirming the effectiveness and safety of Chinese medicine decoctions as adjunctive treatment for diabetic nephropathy. The study explored the sources of heterogeneity through multidimensional analysis, providing evidence-based medicine evidence for further clinical research. However, this study also has some limitations. Due to the significant differences in the composition and dose of the Chinese medicine decoctions included in the studies, there was high heterogeneity in the results. Although most studies lacked clarity regarding the blinding and allocation scheme, as presented in the quality assessment graph, there was no significant impact on our outcome analysis. Most studies sources were searched from Chinese databases consisted of small-sample, single-center studies, leading to publication bias and regional selection bias. Further high-quality experiments are needed to increase the level of evidence.

# 5 Conclusion

In conclusion, this study demonstrates that the combined use of Western medicine and Chinese medicine decoctions can increase clinical efficacy and reduce SCR, UAER, BUN, 24 h-utp, FPG, and HbA1c levels, surpassing the efficacy of using Western medicine alone, without posing significant risks. These results indicate that Chinese medicine decoctions are a safe and effective adjunctive therapy for treating diabetic nephropathy.

## Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

## Author contributions

SZ: Writing-review and editing, Conceptualization, Formal Analysis, Methodology, Project administration. YX: Writing-review and editing, Data curation, Investigation, Visualization. YZ: Writing-review and editing, Funding acquisition, Supervision, Project administration, Validation. GC: Writing-review and editing, Funding acquisition, Supervision, Project administration. ZJ: Writing-review and editing, Funding acquisition, Supervision, Project administration. CL: Writing-review and editing, Supervision, Validation, Visualization. SJ: Writing-review and editing, Supervision, Validation. JC: Writing-review and editing, Data curation. YQ: Writing-review and editing, Data curation. Software.

## Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Funded under a project of the Sichuan Provincial Administration of Traditional Chinese Medicine [Project number: 2023MS419] YZ, GC and ZJ were jointly responsible for project

## References

Aimin, H., Yi, T., Jing, Z., et al. (2018). Clinical study of sugar kidney decoction in the treatment of type 2 diabetic nephropathy Chinese. J. Basic Chin. Med. 24 (01), 80–82. doi:10.19945/j.cnki.issn.1006-3250.2018.01.029

An, Z., Yimin, R., Yongqing, C., et al. (2022). Effects of ginsengqi dihuang tang combined with dagliflozin on renal function, oxidative stress and microinflammation in diabetic nephropathy patients. *Chin. Mater. Medica* 2760–2763. doi:10.13863/j. issn1001-4454.2022.11.041

Angui, J. (2014). Clinical observation of 30 cases of diabetic nephropathy treated with gui zhi fu ling wan. *Sichuan Tradit. Chin. Med.*, 102–103.

Bailong, C., Xiaobo, D., Lifeng, Y., et al. (2015). Effectiveness observation of 41 cases of qi yin deficiency and stasis in diabetic nephropathy stage IV treated with tonifying the kidney and resolving stasis and sugar kidney formula combined with western medicines. *J. Traditional Chin. Med.* 1043–1046. doi:10.13288/j.11-2166/r. 2015.12.015

Barrera-Chimal, J., Lima-Posada, I., Bakris, G. L., and Jaisser, F. (2022). Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. *Nat. Rev. Nephrol.* 18 (1), 56–70. Epub 2021 Oct 21. PMID: 34675379. doi:10.1038/s41581-021-00490-8

Beide, S., and Tingting, T. (2015). Effects of empirical formula of benefiting qi, nourishing yin and activating blood on renal function and blood glucose and lipids in patients with early diabetic nephropathy. *Chin. J. Traditional Chin. Med.* 990–992. doi:10.13193/j.issn.1673-7717.2015.04.068

Bing, Y., and Guobin, M. (2021). Effects of fortifying the spleen, preserving the kidney and clearing the channels on renal function and microinflammatory status in diabetic nephropathy combined with candesartan ester. *Chin. J. Traditional Chin. Med.* 237–240. doi:10.13193/j.issn.1673-7717.2021.04.060

Changsong, Z., Zhensheng, H., and Qingzeng, Q. (2019). Analysis of the therapeutic effect of the method of benefiting qi, nourishing yin, activating blood circulation and removing blood stasis on diabetic nephropathy. *Chin. J. Mod. Med.*, 110–112.

Chenhui, D., Xiaohu, C., and Shuling, P. (2019). Effects of the formula of benefiting qi, nourishing yin and promoting blood stasis on the microinflammatory state of early diabetic nephropathy. J. Nanjing Univ. Chin. Med., 114–117.

management and provided funding. YZ supervised the writing of the manuscript. GC and ZJ provided guidance in pharmacology, GC participated in manuscript revision, and ZJ reviewed and revised the manuscript and will be responsible for subsequent revisions of the manuscript.

## **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2024.1327030/ full#supplementary-material

Chuanfu, Z., Jianrao, L., Xiufeng, C., et al. (2021). Effects of sugar-kidney formula on APN and PAI-1 in phlegm-stasis type IV type 2 diabetic nephropathy and clinical efficacy. *World Sci. Technology-Modernisation Chin. Med.*, 410–416.

Chuanyong, R., et al. (2022). Clinical study of spleen-enhancing and kidney-beneficial tonics combined with epalrestat in the treatment of early diabetic nephropathy. *New Chin. Med.* 54 (17), 111–114.

Cuiqing, Z., Meixing, L., Dongming, W., et al. (2021). Clinical observation on the treatment of early diabetic nephropathy by combining prostaglandin with the addition of ginsengqi dihuang tang and prostaglandin. *Chin. J. Traditional Chin. Med.* doi:10. 13193/j.issn.1673-7717.2022.02.060

Dandan, P. (2020). Clinical study on the treatment of early diabetic nephropathy with blood-boosting and yin-supporting soup. *New Chin. Med.* 52 (12), 76–78. doi:10.13457/j.cnki.jncm.2020.12.023

Duanyang, J., Yanjie, Z., Hao, Z., et al. (2023). Effects of ginsengqi dihuang tang on renal function and microcirculation in patients with early diabetic nephropathy. *New Chin. Med.* 44–47. doi:10.13457/j.cnki.jncm.2023.01.009

Fangqiang, C., Long, T., Yanbin, G., Wang, Y. F., Meng, Y., Shen, C., et al. (2019). Effect of baoshenfang formula on podocyte injury via inhibiting the NOX-4/ROS/ p38 pathway in diabetic nephropathy. *J. Diabetes Res.* 2019, 2981705. doi:10.1155/2019/ 2981705

Gangyi, C., Baolin, S., and Xing, L. (2019). Therapeutic efficacy of the method of benefiting qi, nourishing yin and eliminating stasis in the treatment of diabetic nephropathy with qi and yin deficiency and stasis and its regulatory effect on Th17 and Th22 cytokines. *Chin. J. Traditional Chin. Med.* 669–672. doi:10.13193/j.issn.1673-7717.2019.03.037

Gao, Y., Dong, Y., Guo, Q., Wang, H., Feng, M., Yan, Z., et al. (2022). Study on supramolecules in traditional Chinese medicine decoction. *Molecules* 27 (10), 3268. PMID: 35630743; PMCID: PMC9144598. doi:10.3390/molecules27103268

Gao, Y., Su, X., Xue, T., and Zhang, N. (2023). The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease. *Biomed. Pharmacother.* 163, 114598. Epub 2023 May 5. PMID: 37150034. doi:10.1016/j.biopha.2023.114598

Guo, C., Cao, M., Diao, N., Wang, W., Geng, H., Su, Y., et al. (2023b). Novel pH-responsive E-selectin targeting natural polysaccharides hybrid micelles for diabetic

nephropathy. Nanomedicine 52, 102696. Epub 2023 Jul 1. PMID: 37394108. doi:10. 1016/j.nano.2023.102696

Guo, M., Gao, J., Jiang, L., and Dai, Y. (2023a). Astragalus polysaccharide ameliorates renal inflammatory responses in a diabetic nephropathy by suppressing the TLR4/NFκB pathway. *Drug Des. Devel Ther.* 17, 2107–2118. Published 2023 Jul 19. doi:10.2147/ DDDT.S411211

Haitao, X., Ying, L., Na, S., et al. (2022). Clinical efficacy and foot cell protective effects of a formula that strengthens the spleen, nourishes yin and strengthens astringency on patients with diabetic nephropathy with deficiency of qi and yin. *Chin. J. Exp. Formulas* 28 (09), 103–109. doi:10.13422/j.cnki.syfjx.20220994

Heinrich, M., and Jalil, B. (2023). From the CONSORT to the ConPhyMP statement and beyond-how to ascertain best practice. *Front. Pharmacol.* 14, 1338710. Published 2023 Dec 11. doi:10.3389/fphar.2023.1338710

Hongye, C., Liping, X., Tuanjie, C., et al. (2021). Effects of ginsengqi dihuang tang combined with alfacalcitol soft capsule on inflammatory factors, microalbumin and hormone levels in patients with diabetic nephropathy. *New Chin. Med.* 53 (21), 43–48. doi:10.13457/j.cnki.jncm.2021.21.010

Hou, B., Qiang, G., Zhao, Y., Yang, X., Chen, X., Yan, Y., et al. (2017). Salvianolic acid A protects against diabetic nephropathy through ameliorating glomerular endothelial dysfunction via inhibiting AGE-RAGE signaling. *Cell Physiol. Biochem.* 44 (6), 2378–2394. Epub 2017 Dec 18. pmid: 29262395. doi:10.1159/000486154

Huaizhi, L., Haijuan, Z., Gang, C., et al. (2021). Clinical efficacy of ginseng-maidihuang-tang combined with conventional treatment in patients with early diabetic nephropathy with qi and yin deficiency, 1759–1763.

Huajun, L., Shuquan, L., Qianqian, J., et al. (2018). The efficacy of spleen and kidney strengthening formula in treating diabetic nephrotic syndrome in middleaged and old-aged people and its effect on TCM evidence score, SCr, and BUN indicators. *Liaoning J. Traditional Chin. Med.* 2550–2552. doi:10.13192/j.issn. 1000-1719.2018.12.028

Huang, C. L., Zheng, J. L., Li, F. L., et al. (2016). Effects of Poria cocos polysaccharide on antioxidant capacity and Bax and Bcl-2 protein expression in renal tissues of type 2 diabetic mice. *J. Food Biotechnol.* 35 (01), 82–88.

Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., et al. (2015). The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann. Intern Med.* 162 (11), 777-784. doi:10.7326/m14-2385

International Diabetes Federation (2023). IDF diabetes atlas[EB/OL]. Available at: https://diabetesatlas.org/(Accessed September 24, 2023).

Jiali, Y., and Dong, W. (2023). Clinical study on the treatment of type 2 diabetic nephropathy with deficiency of qi and yin in combination with irbesartan in Angelica sinensis and Liuhuang Tang. *Int. J. Traditional Chin. Med.* 55, 40–43. 02. doi:10.13457/j. cnki.jncm.2023.02.010

Jialing, Y., and Yan, Q. (2015). Clinical study on early diabetic nephropathy with sugar-lowering and kidney-preserving soup. *Chongqing Med.*, 973–975.

Jiang, H., and Fang, L. (2021). Clinical efficacy of ginseng-qi dihuang tang plus flavour in the treatment of diabetic nephropathy with deficiency of qi and yin and blood stasis and its effect on urinary KIM-1 and L-FABP. *Liaoning Univ. Traditional Chin. Med.* 23 (11), 163–166.

Jiangyi, Yu, Qing, Ni, and Su, L. (2022). Diabetic nephropathy: a guide to combined diagnosis and treatment. *J. Traditional Chin. Med.* 63 (02), 190–197. doi:10.13288/j.11-2166/r.2022.02.018

Jianmin, Y. (2015). Analysis of the efficacy of blood-boosting and kidney-benefiting traditional Chinese medicine in the treatment of diabetic nephropathy. Z Chin. J. Traditional Chin. Med. 1396–1398. doi:10.13193/j.issn.1673-7717.2015.06.037

Jili, S., and Hengji, K. (2019). The effects of adding ginseng astragalus dihuang tang combined with telmisartan tablets on the Chinese medicine syndrome score, UARE, and Cys-C in patients with early-stage diabetic nephropathy. *Sichuan Tradit. Chin. Med.*, 117–119.

Jinfeng, S., LiangweiFang, H. H., et al. (2021). Effects of ginsengqi dihuang tang on TGF-β1 and VEGF in diabetic nephropathy. *Liaoning J. Traditional Chin. Med.* 91–95. doi:10.13192/j.issn.1000-1719.2021.07.026

Jingjing, H., Xuebo, C., Wenbo, G., et al. (2015). Clinical efficacy of ginsengqi dihuang tang combined with valsartan in the treatment of early diabetic nephropathy with deficiency of qi and yin. *Chin. J. Traditional Chin. Med.*, 986–990.

Lei, Z., Dehui, H., Zhendong, L., et al. (2022). Clinical study on the treatment of early diabetic nephropathy by combining Si jun Zi tang and liu Wei di huang tang. *New Chin. Med.* 49–52. doi:10.13457/j.cnki.jncm.2022.06.012

Li, T., Changbin, L., Qiang, W., et al. (2022). Therapeutic effect of Yiqi, Nourishing Yin and Tongluo Tang in patients with diabetic nephropathy (stage III-IV) with deficiency of qi and yin and blood stasis. *Chin. Mater. Medica* 2489–2493. doi:10. 13863/j.issn1001-4454.2022.10.041

Lige, L. (2016). Clinical study on the treatment of diabetic nephropathy with qi and yin deficiency and stasis obstruction by combining ginseng qi di huang tang with peach kernel cheng qi tang. *Liaoning J. Traditional Chin. Med.* 2115–2117. doi:10.13192/j.issn. 1000-1719.2016.10.032

Ling, W. (2019). Effects of Zi Kidney and Qi Formula combined with Irbesartan on renal fibrosis indexes and inflammatory factors in diabetic nephropathy, 940–943.

Liping, T., Xuefeng, P., Yuhua, M., et al. (2014). A phase IV clinical study of hypoglycaemic Kangkang Kidney Soup combined with western medicine in the treatment of diabetic nephropathy. *Liaoning J. Chin. Med.* 1934–1936. doi:10.13192/j.issn.1000-1719.2014.09.060

Liu, J., Gao, L. D., Fu, B., Yang, H. T., Zhang, L., Che, S. Q., et al. (2022). Efficacy and safety of Zicuiyin decoction on diabetic kidney disease: a multicenter, randomized controlled trial. *Phytomedicine* 100, 154079. doi:10.1016/j.phymed.2022.154079

Liwen, P., Dinghua, Z., Dongpeng, Z., et al. (2018). Clinical observation of tonifying the kidney and benefiting qi to pass the collaterals and resolve turbidities in the treatment of early diabetic nephropathy New. *Chin. Med.* 50 (9), 98–101. doi:10.13457/j. cnki.jncm.2018.09.028

Long, C., Feng, H., Liu, Z., Li, Z., Liu, J., Jiang, Y., et al. (2023). Efficacy of traditional Chinese medicine injection for diabetic kidney disease: a network meta analysis and systematic review. *Front. Pharmacol.* 14, 1028257. Published 2023 Feb 17. doi:10.3389/fphar.2023.1028257

Ma, W., Wang, K. J., Cheng, C. S., Yan, G. Q., Lu, W. L., Ge, J. F., et al. (2014). Bioactive compounds from Cornus officinalis fruits and their effects on diabetic nephropathy. J. Ethnopharmacol. 153 (3), 840–845. doi:10.1016/j.jep.2014.03.051

Meizhen, L., Sui, L., and Riming, X. (2022). Application of Qidi Renkang Tang combined with prostaglandin in the treatment of diabetic nephropathy and its effect on serum sICAM-1 and urinary CTGF levels. *Chin. J. Traditional Chin. Med.* 203–206. doi:10.13193/j.issn.1673-7717.2022.04.046

Min, Z., Biying, L., and Xiaokun, L. (2018). Clinical observation on the treatment of early diabetic nephropathy (qi and yin deficiency type) with ginsengqi dihuang tang combined with valsartan. *Chin. J. Traditional Chin. Med.*, 3206–3208.

Ming, L., Xiaoqiang, L., and Huanjun, Z. (2015). Clinical study on the treatment of early diabetic nephropathy with ginsengqi dihuang tang, 1116–1118.

Naaman, S. C., and Bakris, G. L. (2023). Diabetic nephropathy: update on pillars of therapy slowing progression. *Diabetes Care* 46 (9), 1574–1586. PMID: 37625003. doi:10. 2337/dci23-0030

National Pharmacopoeia Committee (2020). *Pharmacopoeia of the people's Republic of China [EB/OL]*. Pharmacopoeia of the People's Republic of China. Available at: https://ydz.chp.org.cn/#/main (Accessed December 31 2023).

Ni, Z., Xinrong, X., Qaioling, Z., et al. (2017). Clinical efficacy of Chinese medicine combined with telmisartan tablets in the treatment of type 2 diabetic nephropathy. *Chin. J. Traditional Chin. Med.* 2148–2150. doi:10.13193/j.issn.1673-7717.2017.08.062

Ping, D., and Lin, A. (2017). Clinical observation of 35 cases of early diabetic nephropathy treated with ginseng qi di huang tang. *Tianjin Chin. Med.*, 239–241.

Ping, W., Xiaotang, Q., and Henan, L. (2022). Effects of spleen and kidney strengthening formula on pancreatic and renal functions in early diabetic nephropathy with deficiency of spleen and kidney. *Chin. J. Traditional Chin. Med.* 79–81. doi:10.13193/j.issn.1673-7717.2022.07.020

Rivera, D., Allkin, R., Obón, C., Alcaraz, F., Verpoorte, R., and Heinrich, M. (2014). What is in a name? The need for accurate scientific nomenclature for plants. *J. Ethnopharmacol.* 152 (3), 393–402. doi:10.1016/j.jep.2013.12.022

Rong, Y., and Xiabo, C. (2019). Clinical study of stabilising sugar, preserving kidney and eliminating symptoms in combination with conventional therapy for treating stage III diabetic nephropathy. *New Chin. Med.* 51 (05), 170–172. doi:10.13457/j.cnki.jncm.2019.05.051

Rucui, Y., Zhihui, L., and Ping, L. (2017). Clinical study on the treatment of early diabetic nephropathy by benefiting qi, nourishing yin and promoting collaterals formula[J]. *J. Nanjing Univ. Traditional Chin. Med.* 33 (1), 101–103.2. doi:10.14148/j.issn.1672-0482.2017.0101

Ruixuan, W., Jinguo, C., Zhanghong, L., et al. (2023). Effects of ginsengqi dihuang tang on renal function and microinflammation in patients with diabetic nephropathy stage IV-V. *Liaoning J. Chin. Med.* 157–160. doi:10.13192/j.issn.1000-1719.2023.06.043

Shi, R. Y., Zhang, L. Q., Zhang, K. X., Li, Q. R., Wang, X. X., and Yang, K. (2023). Network Meta-analysis of efficacy of Chinese patent medicine in treatment of inflammatory response in diabetic nephropathy. *Zhongguo Zhong Yao Za Zhi* 48 (13), 3633–3649. doi:10.19540/j.cnki.cjcmm.20230330.501

Shijian, Q., and Chunying, W. (2018). Clinical observation on the treatment of early diabetic nephropathy by benefiting qi, activating blood and fixing kidney. *New Chin. Med.*, 84–86.

Shulan, W., Yanping, Z., Hua, Y., et al. (2016). Clinical study on the treatment of stage IV diabetic nephropathy with spleen-kidney yang deficiency by adding flavour Zhenwu Tang. J. Nanjing Univ. Traditional Chin. Med. 220–223. doi:10.14148/j.issn.1672-0482. 2016.0220

Sun, L., Yang, Z., Zhao, W., Chen, Q., Bai, H., Wang, S., et al. (2022). Integrated lipidomics, transcriptomics and network pharmacology analysis to reveal the mechanisms of Danggui Buxue Decoction in the treatment of diabetic nephropathy in type 2 diabetes mellitus. *J. Ethnopharmacol.* 283, 114699. doi:10.1016/j.jep.2021. 114699

Suqin, W., Meixiao, S., Cuiping, Z., et al. (2019). Therapeutic efficacy of Tongluo subduing turbid and benefiting the kidney method in treating patients with diabetic

nephropathy in the early and middle stages of diabetes mellitus and its effect on serum inflammatory factors. *Chin. Mater. Medica* 920–923. doi:10.13863/j.issn1001-4454. 2019.04.045

Tang, D., Shen, Y. B., Wang, Z. H., He, B., Xu, Y. H., Nie, H., et al. (2018). Rapid analysis and guided isolation of Astragalus isoflavonoids by UHPLC-DAD-MSn and their cellular antioxidant defense on high-glucose-induced mesangial cell dysfunction. *J. Agric. Food Chem.* 66 (5), 1105–1113. epub 2018 Jan 26. pmid: 29091441. doi:10.1021/acs.jafc.7b02949

Tao, L., Zhi, G., Jianhua, W., et al. (2016). Clinical observation on treatment of stage IV diabetic nephropathy with spleen and kidney qi deficiency by benefiting qi and tonifying kidney formula. *Chin. J. Traditional Chin. Med.* 2557–2560. doi:10.13193/j. issn.1673-7717.2016.10.072

Ting, Z., Yanbin, G., and Wenming, Y. (2015). Warming the kidney and strengthening the spleen, resolving blood stasis and clearing collaterals in the treatment of diabetic nephropathy in the clinical stage. *Chin. J. Exp. Formulas* 200–203. doi:10.13422/j.cnki.syfjx.2015200200

Trustees of the Royal Botanic Gardens, Kew (2023). Kew science medical plant name services. Available at: http://mpns.kew.org/mpns-portal/(Accessed December 31, 2023).

Wang, B., Lin, L., Ni, Q., and Su, C. L. (2011). Chinese medicine for treating diabetic nephropathy. *Chin. J. Integr. Med.* 17 (10), 794–800. doi:10.1007/s11655-011-0880-2

Wang, M. R., Yu, L. H., Wang, T. T., Wang, Y. M., and Han, M. X. (2018). Effect of Shenqi Dihuang decoction on inflammatory factor, renal function and microcirculation in patients with early diabetic nephropathy. *Zhongguo Zhong Yao Za Zhi* 43 (6), 1276–1281. PMID: 29676140 Chinese. doi:10.19540/j.cnki.cjcmm.2018.0050

Wei, H., Tingxiong, F., Aiping, D., et al. (2020). Therapeutic effect of kidneystrengthening, spleen-strengthening and dampness-resolving formula combined with candesartan ester in diabetic nephropathy. *Chin. J. Traditional Chin. Med.* 236–239. doi:10.13193/j.issn.1673-7717.2020.07.055

Wu, Q., Guan, Y. B., Zhang, K. J., Li, L., and Zhou, Y. (2023). Tanshinone IIA mediates protection from diabetes kidney disease by inhibiting oxidative stress induced pyroptosis. *J. Ethnopharmacol.* 316, 116667. Epub 2023 May 29. PMID: 37257702. doi:10.1016/j.jep.2023.116667

Xiaojing, D., Yue, Y., Tao, T., et al. (2016). Clinical study on the treatment of earlystage diabetic nephropathy with the method of "Xuankai xuanfu, clearing heat and removing turbidity. *Shizhen Guojian*, 1426–1428.

Xiaoli, Z., Yun, X., Hua, X., et al. (2017). Observation on the efficacy of Yiqi Huayu Tang combined with western medicines in the treatment of early diabetic nephropathy and the effect on vascular endothelial function. *New Chin. Med.* 49 (04), 39–42. doi:10. 13457/j.cnki.jncm.2017.04.013

Xiaomei, D., Wei, P., Yinglan, L., et al. (2021). Effect of adding ginseng and astragalus dihuang soup on the treatment of diabetic nephropathy with deficiency of qi and yin and on intestinal flora and inflammatory factors. *Chin. Med. New Drugs Clin. Pharmacol.* 32 (04), 566–572. doi:10.19378/j.issn.1003-9783.2021.04.018

Xiaoyi, Z. (2018). Clinical observation on the treatment of early diabetic nephropathy with the formula of benefiting qi, nourishing yin and activating blood. *New Chin. Med.* 50 (01), 60–63. doi:10.13457/j.cnki.jncm.2018.01.016

Xiaoze, S., Gaofeng, T., and Aihua, L. (2019). Effects of the addition and subtraction of Quenching Thirst Formula on endothelial damage, oxidative stress and biochemical indexes in diabetic nephropathy with deficiency of qi and yin and stasis. *Chin. J. Exp. Formulas* 43–48. doi:10.13422/j.cnki.syfjx.20190830

Xin, Y., Jie, X., Danhong, X., et al. (2023). Clinical study of tonifying Yang and restoring Wu Tang combined with dagliflozin in the treatment of early diabetic nephropathy, 59–62.

Xingguo, L., Dongchen, D., and Mingjie, F. (2018). Effect of six flavour dihuang pill combined with shengwei tang plus and minus in the adjuvant treatment of early and middle stage diabetic nephropathy and change of serum Cys-C level. *Shandong Med.*, 73–75.

Xinxin, P., Xiujie, S., and Yage, Z. (2020). Clinical efficacy of Tongluo Di Gui Tang in the treatment of type 2 diabetic nephropathy stage IV patients. *Chin. Fam. Med.*, 3846–3850.

Xue, F., Bin, P., and Zhi, G. (2023). Efficacy of kidney detoxification formula in the treatment of elderly patients with diabetic nephropathy and its effect on 24-h urine protein and  $\beta$ 2-microglobulin. *Liaoning J. Chin. Med.* 119–122. doi:10.13192/j.issn. 1000-1719.2023.03.034

Yalan, H., Guodong, H., Linkun, C., et al. (2020). Clinical observation on the treatment of early diabetic nephropathy with spleen and kidney deficiency and dampness-heat and blood stasis by combining tonifying Yang Huiwu Tang and Sanren Tang. *Chin. J. Exp. Formulas* 60–68. doi:10.13422/j.cnki.syfjx.20200425

Yali, Z., Tingzhen, L., Weihuan, W., et al. (2020). Clinical efficacy of Qizhu Di Huang Wan plus flavour combined with exenatide in early diabetic nephropathy with liver and kidney yin deficiency and stasis. *Liaoning J. Traditional Chin. Med.* 95–97. doi:10. 13192/j.issn.1000-1719.2020.07.026

Yalian, H. (2014). Therapeutic efficacy of tonic Yuan Tongluo Tang combined with Irbesartan in the treatment of diabetic nephropathy stage III in 31 patients. J. Traditional Chin. Med. 946–948. doi:10.13288/j.11-2166/r.2014.11.013

Yan, C., Menghua, L., and Fanxiang, W. (2022). Effect of ginsengqi dihuangtang on the efficacy of ginsengqi dihuangtang on diabetic nephropathy in the elderly and the effect of serum KIM-1 and VEGF. *Liaoning J. Chin. Med.* 88–91. doi:10.13192/j.issn. 1000-1719.2022.04.024

Yangxi, F., Xiaotang, Q., Wenkui, Y., et al. (2019). A phase IV clinical study on the treatment of diabetic nephropathy with qi and yin deficiency and blood stasis by adding and subtracting ginsengqi dihuang tang. *Chin. J. Traditional Chin. Med.* 2036–2039. doi:10.13193/j.issn.1673-7717.2019.12.050

Yangxia, L., Fan, M., Yunlei, Z., et al. (2019). Effects of blood-boosting and kidneybenefiting formula combined with prostaglandin on renal function and haemodynamic levels in patients with diabetic nephropathy New Chinese Medicine. *Front. Pharmacol.* 51 (08), 137–140. doi:10.13457/j.cnki.jncm.2019.08.041

Yi, S., and Mianzhi, S. (2013). Observation on the efficacy of tonifying the kidney and activating blood in treating diabetic nephropathy in the clinical stage. *J. Beijing Univ. Chin. Med.*, 353.

Ying, L., Yanling, L., Sumin, Z., et al. (2021). Effects of Jiankui Huayu Tang combined with prostaglandin on haemorheology and renal function in early diabetic nephropathy. *Chin. J. Traditional Chin. Med.* 67–69. doi:10.13193/j.issn.1673-7717.2021.11.017

Yu, Z., Jianping, L., and Yuanli, Z. (2022). Clinical efficacy of Zhenwu Tang plus reduction combined with chlorosartan potassium tablets in the treatment of early to mid-stage diabetic nephropathy in the elderly and its effect on TLR4/MyD88 pathway. *Chin. J. Gerontology*, 1687–1690.

Zhang, T., Chen, X., Zhou, Z., Zhong, G., and Guo, J. (2004). Clinical Chinese medicine. ISBN 7-80256-568-1. Vol. 1. China press of traditional Chinese medicine.

Zhixiong, T., Jianying, Z., and Fusheng, C. (2019). Clinical study of Qi Tian Tang combined with potassium cloxartan tablets in the treatment of early diabetic nephropathy. *J. Pract. Med.*, 1500–1503.

Zhong, Y., Jin, R., Luo, R., Liu, J., Ren, L., Zhang, Y., et al. (2023). Diosgenin targets CaMKK2 to alleviate type II diabetic nephropathy through improving autophagy, mitophagy and mitochondrial dynamics. *Nutrients* 15 (16), 3554. PMID: 37630743; PMCID: PMC10459415. doi:10.3390/nu15163554